{"gene":"CSF3","run_date":"2026-04-28T17:28:53","timeline":{"discoveries":[{"year":1986,"finding":"The gene encoding human G-CSF (CSF3) was cloned from a squamous carcinoma cell line (CHU-2); the cDNA expressed in COS cells produced a protein with authentic G-CSF activity. Two mRNA isoforms arise from alternative splicing of the second intron. The mature secreted protein is O-glycosylated (Thr-133) with MW ~19,600 Da.","method":"cDNA cloning, COS cell expression, competitive radioligand binding assay, biochemical characterization","journal":"Nature / EMBO Journal","confidence":"High","confidence_rationale":"Tier 1 — original cloning and expression with functional validation, independently replicated (two papers)","pmids":["3484805","2423327"],"is_preprint":false},{"year":1986,"finding":"Recombinant human G-CSF (expressed in E. coli) supports neutrophil colony formation (CFU-GM assay), induces terminal differentiation of WEHI-3B(D+) myelomonocytic leukemia cells, and supports early erythroid and mixed colonies. Leukemic cells bearing G-CSF receptors (demonstrated by 125I-labeled ligand binding) undergo terminal differentiation to macrophages and granulocytes.","method":"Recombinant protein expression, CFU-GM colony assay, competitive radioligand binding, cell differentiation assays","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — reconstituted recombinant protein with multiple orthogonal functional assays","pmids":["2420009"],"is_preprint":false},{"year":1990,"finding":"Natural and recombinant human G-CSF both contain a free Cys-17 and two intramolecular disulfide bonds (Cys-36/Cys-42 and Cys-64/Cys-74), with O-glycosylation at Thr-133; both forms exhibit equivalent biological activity in vitro and in vivo.","method":"Protein purification, amino acid sequencing, biochemical disulfide mapping, CD spectroscopy, colony-forming and in vivo bioassays","journal":"Journal of biochemistry","confidence":"High","confidence_rationale":"Tier 1 — direct structural and biochemical characterization of purified natural and recombinant protein","pmids":["1692828"],"is_preprint":false},{"year":1991,"finding":"Two alternatively spliced forms of the G-CSF receptor (G-CSFR) both transduce G-CSF proliferative signals when expressed in IL-3-dependent BAF/BO3 or IL-6-dependent B9 cells. A cytoplasmic-domain deletion mutant fails to confer G-CSF responsiveness, indicating that the first 96 amino acids of the cytoplasmic domain are required for signal transduction.","method":"cDNA transfection into cytokine-dependent cell lines, growth assays, radioligand binding","journal":"The New biologist","confidence":"High","confidence_rationale":"Tier 1 — reconstitution of receptor signaling with deletion mutagenesis defining essential cytoplasmic domain","pmids":["1725961"],"is_preprint":false},{"year":1993,"finding":"X-ray crystal structure of recombinant human G-CSF at 2.2 Å resolution reveals a four-α-helix bundle with up-up-down-down connectivity, placing it in the same structural superfamily as growth hormone, GM-CSF, interferon-β, IL-2, and IL-4, suggesting a conserved receptor-binding mechanism.","method":"X-ray crystallography (multiple isomorphous replacement, 2.2 Å resolution)","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with full refinement at high resolution","pmids":["7685117"],"is_preprint":false},{"year":1995,"finding":"G-CSF is cleared from the body primarily via receptor-mediated endocytosis in bone marrow; elimination is saturable with a Km (~107 pM) matching the receptor dissociation constant (Kd), and receptor downregulation after excess G-CSF reduces tissue uptake clearance, which recovers as receptors are replenished.","method":"Steady-state infusion pharmacokinetics in rats, 125I-labeled ligand tissue uptake assays, cyclophosphamide and repeated-dosing receptor modulation experiments","journal":"The American journal of physiology","confidence":"High","confidence_rationale":"Tier 1–2 — quantitative in vivo pharmacokinetic-receptor binding analysis with multiple experimental conditions","pmids":["7543246"],"is_preprint":false},{"year":2002,"finding":"rhG-CSF aggregation under physiological conditions (pH 6.9, 37°C) proceeds through a reversible dimer intermediate that does not itself participate in irreversible aggregation; sucrose stabilizes the native monomeric state by thermodynamic preferential exclusion, reducing the population of structurally expanded intermediates that seed aggregation.","method":"Biochemical aggregation assays, hydrogen-deuterium exchange, thermal unfolding, sucrose stabilization experiments","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal biophysical methods establishing mechanism of aggregation","pmids":["12009905"],"is_preprint":false},{"year":2002,"finding":"G-CSF receptor (G-CSFR) engages the Jak2 and Lyn non-receptor tyrosine kinases upon ligand binding. Lyn phosphorylates c-Cbl, which couples to PI3-kinase; the c-Cbl/PI3-kinase pathway is required for G-CSF-induced proliferative (DNA synthesis) signaling, whereas Jak-STAT activation alone is insufficient for proliferation.","method":"Yeast two-hybrid (Lyn–c-Cbl–PI3K coupling), antisense knockdown of c-Cbl in DT40 cells expressing G-CSFR, Jak-STAT and PI3-kinase activity assays, DNA synthesis measurement","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2–3 — epistasis established in cell model with multiple signaling readouts, single lab","pmids":["12149655"],"is_preprint":false},{"year":2004,"finding":"SOCS3 is a key negative regulator of G-CSF signaling in myeloid cells: hematopoietic-specific Socs3-knockout mice display prolonged STAT3 activation and enhanced cellular responses to G-CSF (increased cloning frequency, survival, proliferation, neutrophilia, and progenitor mobilization), demonstrating that SOCS3 normally limits the amplitude and duration of G-CSF/STAT3 signaling.","method":"Conditional Socs3 gene knockout (hematopoietic cells), in vitro G-CSF stimulation assays, in vivo G-CSF injection, phospho-STAT3 Western blot","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — genetic loss-of-function with multiple orthogonal in vitro and in vivo readouts, well-cited","pmids":["14975238"],"is_preprint":false},{"year":2005,"finding":"G-CSF acts directly on cardiomyocytes (which express G-CSF receptor) and activates the Jak/STAT3 pathway; this signaling induces anti-apoptotic proteins, reduces cardiomyocyte and endothelial cell apoptosis, and increases vascularization after myocardial infarction. Overexpression of dominant-negative STAT3 in cardiomyocytes abolishes all these protective effects.","method":"Dominant-negative STAT3 transgenic mice, G-CSF receptor immunostaining on cardiomyocytes, Jak/STAT phosphorylation assays, apoptosis assays, cardiac function measurement, vascularization histology","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 — genetic dominant-negative rescue approach with multiple orthogonal readouts, highly cited","pmids":["15723072"],"is_preprint":false},{"year":2005,"finding":"Stat3 functions as a negative regulator of G-CSF signaling by inducing SOCS3 expression: Stat3-deficient hematopoietic cells have near-absent SOCS3, sustained ERK1/2 activation (not STAT3) in response to G-CSF, and augmented G-CSF-driven proliferation that is abolished by MEK1 inhibition.","method":"Conditional Stat3-knockout bone marrow cells, G-CSF stimulation, phospho-ERK/STAT3 Western blot, MEK1 inhibitor (PD98059), colony proliferation assays","journal":"Stem cells","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with pharmacologic epistasis, multiple signaling readouts","pmids":["15671148"],"is_preprint":false},{"year":2005,"finding":"G-CSF potently suppresses osteoblast activity and reduces CXCL12 (SDF-1) mRNA/protein expression in bone marrow via an indirect mechanism (G-CSF receptor is not expressed on osteoblasts); the degree of CXCL12 reduction correlates with the degree of hematopoietic progenitor cell (HPC) mobilization across transgenic G-CSFR mouse lines with different mobilization capacities.","method":"G-CSFR transgenic mouse series with variable mobilization, cell sorting, osteoblast histomorphometry, osteocalcin expression, CXCL12 mRNA/protein quantification","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — genetic series of receptor mutant mice + cell sorting + molecular correlation, well-cited","pmids":["16037394"],"is_preprint":false},{"year":2006,"finding":"G-CSF directly down-regulates CXCR4 expression on myeloid (Gr1+) bone marrow cells in a time-dependent manner, reducing their responsiveness to SDF-1 in attachment and migration assays, thereby promoting their mobilization to peripheral blood; non-myeloid cells show no CXCR4 change.","method":"Flow cytometry of CXCR4 surface expression, SDF-1 migration/attachment assays, in vivo G-CSF mobilization in mice","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — direct cell-surface receptor quantification with functional migration assays, in vitro and in vivo confirmation","pmids":["16537807"],"is_preprint":false},{"year":2006,"finding":"G-CSF induces the transcriptional repressor Gfi-1 in myeloid cells; Gfi-1 binds to DNA sequences upstream of the CXCR4 gene and represses CXCR4 transcription, thereby reducing SDF-1 responsiveness and facilitating granulocytic cell mobilization from bone marrow.","method":"In vitro and in vivo G-CSF treatment, Gfi-1 expression analysis, chromatin immunoprecipitation (ChIP) at CXCR4 promoter, migration assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — ChIP demonstrating direct Gfi-1 binding to CXCR4 promoter plus functional migration assays","pmids":["17596540"],"is_preprint":false},{"year":2006,"finding":"G-CSF promotes expression of E-selectin ligands (HCELL and a ~65 kDa ligand) on mobilized human myeloid cells by upregulating glycosyltransferases (ST3GalIV, FucT-IV, FucT-VII), resulting in heightened E-selectin-mediated adhesion to inflamed endothelium under physiological flow conditions.","method":"Parallel-plate flow assay, intravital microscopy, flow cytometry, enzymatic treatments, glycosyltransferase transcript quantification, in vitro G-CSF treatment of bone marrow","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (flow, intravital microscopy, enzymatic, molecular) in both ex vivo and in vivo systems","pmids":["16980970"],"is_preprint":false},{"year":2006,"finding":"G-CSF receptor is expressed on dopaminergic neurons in the substantia nigra; G-CSF activates the ERK pathway (not JAK/STAT) in these neurons, increases phospho-Bad and Bcl-xL, inhibits 6-OHDA-induced caspase-3 activation, and protects dopaminergic neurons from 6-OHDA neurotoxicity; ERK inhibition abrogates all neuroprotective effects.","method":"Immunostaining for G-CSFR in substantia nigra and mesencephalic cultures, 6-OHDA neurotoxicity model, phospho-ERK/Bad/Bcl-xL Western blot, caspase-3 activity, MEK/ERK inhibitor epistasis","journal":"Neurobiology of aging","confidence":"Medium","confidence_rationale":"Tier 2 — pathway placement by pharmacologic inhibitor epistasis with multiple molecular readouts, single lab","pmids":["16839644"],"is_preprint":false},{"year":2006,"finding":"The G-CSF receptor has a 2:2 stoichiometry with G-CSF, with two binding sites on both the ligand and receptor equivalent to sites II and III of the IL-6/gp130 receptor complex, as established by mapping of neutralizing antibody binding sites, solution studies of receptor fragments, and mutagenesis, validated against the crystal structure of gp130 bound to viral IL-6.","method":"Neutralizing antibody epitope mapping, solution binding studies with receptor fragments, site-directed mutagenesis, comparative structural modeling","journal":"Frontiers in bioscience","confidence":"Medium","confidence_rationale":"Tier 1–2 — structural model supported by mutagenesis and solution binding, but final structure is modeled not crystallized","pmids":["16720384"],"is_preprint":false},{"year":2007,"finding":"SOCS3 controls lysosomal routing of G-CSFR: a juxtamembrane lysine residue (K632) is required for SOCS3-mediated ubiquitination and routing of G-CSFR to lysosomes. Mutation of K632 causes G-CSFR accumulation in early endosomes and sustained activation of STAT5 and ERK (but not PKB/Akt), and perturbs the proliferation/differentiation balance in myeloid progenitors.","method":"K632 point mutagenesis of G-CSFR, endosomal fractionation/localization, phospho-STAT5/ERK/Akt Western blot, ubiquitination assays, myeloid differentiation assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1–2 — site-directed mutagenesis with subcellular fractionation, multiple signaling readouts, and functional differentiation phenotype","pmids":["17363902"],"is_preprint":false},{"year":2008,"finding":"SAA (serum amyloid A) induces G-CSF expression and neutrophilia via TLR2: SAA stimulates G-CSF mRNA and protein in macrophages, activates NF-κB binding to the CK-1 element of the G-CSF promoter, and this induction is blocked by anti-TLR2 antibody, absent in TLR2-deficient macrophages, and abolished in vivo in G-CSF- or TLR2-deficient mice.","method":"Anti-TLR2 antibody blocking, TLR2-KO macrophages, in vitro reconstitution, G-CSF KO mice, NF-κB EMSA, in vivo neutrophilia measurement","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — genetic KO + antibody blocking + in vitro reconstitution with promoter-binding data","pmids":["18952897"],"is_preprint":false},{"year":2010,"finding":"Transcription factor Gfi1 promotes expression of RasGRP1 (a Ras guanine nucleotide exchange factor) in myeloid cells; RasGRP1 is required for G-CSF to activate Ras/MEK/ERK signaling. Gfi1-null cells fail to activate ERK in response to G-CSF and cannot differentiate into neutrophils; re-expression of RasGRP1 in Gfi1-deficient cells rescues ERK activation and neutrophil maturation by G-CSF.","method":"Gfi1-knockout mice, G-CSF stimulation with phospho-ERK/STAT1/STAT3 Western blot, RasGRP1 re-expression rescue, neutrophil differentiation assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — genetic KO + gain-of-function rescue with specific pathway readouts","pmids":["20203268"],"is_preprint":false},{"year":2011,"finding":"G-CSF receptor (G-CSFR) is expressed on myoblasts during embryonic somite development and transiently on regenerating myocytes in injured adult muscle; neutralization of endogenous G-CSF impairs skeletal muscle regeneration, exogenous G-CSF promotes regeneration by stimulating myoblast proliferation, and G-CSFR-knockout mice show markedly impaired muscle regeneration.","method":"G-CSFR immunostaining in developing and regenerating muscle, G-CSF neutralizing antibody, recombinant G-CSF administration, G-CSFR-KO mice, BrdU myoblast proliferation assay","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — genetic KO + neutralizing antibody + exogenous protein with defined proliferation readout","pmids":["21422169"],"is_preprint":false},{"year":2011,"finding":"G-CSF induces rapid induction of CXCL1 (KC) in bone marrow via a thrombopoietin (TPO)-mediated pathway: G-CSF rapidly increases BM TPO levels, TPO stimulates megakaryocytes and endothelial cells to release KC, KC then activates CXCR2 on neutrophils to induce their motility and vascular entry; mice lacking CXCR2 or the TPO receptor show impaired G-CSF-driven neutrophil mobilization.","method":"Intravital 2-photon microscopy, CXCR2-KO and TPO-receptor-KO mice, CXCR2-blocking antibody, intravital chemokine spike measurement, megakaryocyte isolation and KC secretion assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — intravital imaging + multiple genetic KOs + antibody blocking with orthogonal functional assays","pmids":["21224471"],"is_preprint":false},{"year":2011,"finding":"G-CSF improves G6PC3-deficient neutrophil function in vivo by normalizing PI3K/Akt signaling, reducing caspase-3 activity, and restoring energy homeostasis (increased glucose uptake, elevated G6P, lactate, and ATP), thereby correcting both neutropenia and functional deficits.","method":"G6pc3-KO mice, in vivo G-CSF therapy, flow cytometric apoptosis (caspase-3, PI3K/Akt), metabolic assays (glucose uptake, G6P, lactate, ATP), neutrophil functional assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic model with multiple orthogonal biochemical and functional readouts","pmids":["21292774"],"is_preprint":false},{"year":2015,"finding":"G-CSF activates autophagy in neutrophils and hematopoietic stem cells (HSCs); G-CSF-induced neutrophil and HSC mobilization is impaired in autophagy-deficient animals, whereas direct HSC mobilization by AMD3100 (CXCR4 antagonist) is autophagy-independent, demonstrating that autophagy is specifically required for G-CSF-dependent mobilization.","method":"Autophagy-deficient mice, G-CSF and AMD3100 mobilization assays, autophagy flux assays in human and mouse neutrophils and HSCs","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — genetic autophagy deficiency + pharmacologic comparator + both mouse and human cells","pmids":["25788702"],"is_preprint":false},{"year":2015,"finding":"ERK2 (but not ERK1) specifically mediates LPS-induced G-CSF expression in macrophages: shRNA knockdown of ERK2 (not ERK1) reduces LPS-stimulated G-CSF promoter activity, mRNA, and protein; ERK2 synergizes with C/EBPβ to activate the G-CSF promoter, and ERK2 is required for LPS-induced chromatin remodeling (DNase I accessibility) and NF-κB/C/EBPβ binding at the G-CSF promoter.","method":"shRNA knockdown (ERK1 vs ERK2), G-CSF promoter reporter assay, ChIP for NF-κB p50/p65 and C/EBPβ, DNase I sensitivity assay, MEK1/2 inhibitor (U0126)","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — isoform-specific knockdown + promoter assays + ChIP, single lab","pmids":["26114754"],"is_preprint":false},{"year":2019,"finding":"Trauma-induced emergency hematopoiesis is driven by an IL-1/MyD88-dependent pathway that increases G-CSF production; G-CSF then expands hematopoietic stem cells and multipotent progenitors and increases myeloid-skewed progenitor frequency.","method":"Mouse polytrauma model, MyD88-KO and IL-1-pathway-KO mice, G-CSF ELISA, hematopoietic progenitor flow cytometry","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO pathway epistasis with defined hematopoietic readout, single lab","pmids":["30988118"],"is_preprint":false},{"year":2020,"finding":"Cancer-associated adipocyte (CAA)-derived G-CSF promotes breast cancer cell epithelial-mesenchymal transition, migration, and invasion via STAT3 activation; G-CSF upregulates MMP2 and MMP9 as STAT3 target genes; these effects are abrogated by G-CSF-neutralizing antibody, chemical STAT3 inhibitor, or STAT3 siRNA.","method":"Co-culture of primary CAAs with TNBC cell lines, recombinant G-CSF treatment, G-CSF neutralizing antibody, STAT3 siRNA/inhibitor, migration/invasion assays, MMP2/MMP9 Western blot","journal":"Journal of molecular cell biology","confidence":"Medium","confidence_rationale":"Tier 2–3 — multiple inhibition strategies converging on STAT3/MMP axis, single lab","pmids":["32242230"],"is_preprint":false},{"year":2021,"finding":"MLKL controls the release of G-CSF from leukemic hematopoietic progenitor cells by associating with early endosomes and mediating plasma membrane pore formation to release intracellularly stored G-CSF; Mlkl-knockout cells retain G-CSF mRNA expression and protein translation but release significantly less G-CSF, impairing myeloid differentiation.","method":"Mlkl-knockout gene-targeted mice, intracellular G-CSF protein quantification, G-CSF secretion assay, endosomal co-localization (MLKL/early endosome markers), plasma membrane pore formation assay, myeloid differentiation assays","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO with organelle colocalization and functional secretion assay, single lab","pmids":["34079078"],"is_preprint":false},{"year":2021,"finding":"M2 macrophage-derived G-CSF promotes trophoblast EMT, migration, and invasion via activation of the PI3K/Akt/ERK1/2 signaling pathway; knockdown or inhibition of these pathways abolishes G-CSF-stimulated trophoblast invasiveness.","method":"Co-culture of macrophages with trophoblast cell lines, recombinant G-CSF treatment, PI3K/Akt/ERK1/2 pathway inhibitors, migration/invasion assays, EMT marker Western blot","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2–3 — pharmacologic pathway epistasis with functional assays, single lab","pmids":["33393205"],"is_preprint":false},{"year":2023,"finding":"G-CSF is the principal driver of autoinflammation in APLAID (PLCG2 p.Ser707Tyr mutation): APLAID mice show markedly elevated G-CSF levels (the most distinct cytokine feature); anti-G-CSF antibody treatment completely reverses established disease, normalizes myelopoiesis, and restores lymphocyte numbers; bone marrow transplantation from healthy donors rescues APLAID mice and reduces G-CSF predominantly from non-hematopoietic cells.","method":"APLAID knock-in mouse model, anti-G-CSF antibody therapeutic intervention, bone marrow transplantation, cytokine profiling, flow cytometry of immune populations","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 — genetic disease model + antibody rescue + BMT rescue, multiple orthogonal readouts","pmids":["36997670"],"is_preprint":false}],"current_model":"CSF3 (G-CSF) is a secreted four-α-helix bundle glycoprotein (O-glycosylated at Thr-133, two disulfide bonds Cys-36/42 and Cys-64/74) that binds its homodimeric receptor (G-CSFR) in a 2:2 stoichiometry, triggering recruitment of Jak2 and Lyn kinases; Jak2 activates STAT3 (which induces SOCS3 as a negative feedback brake) while Lyn couples via c-Cbl to PI3K/Akt and to ERK via RasGRP1/Gfi1, driving myeloid progenitor proliferation, survival, and neutrophil differentiation; G-CSF mobilizes hematopoietic stem/progenitor cells by indirectly suppressing osteoblast activity and CXCL12 expression, by directly down-regulating CXCR4 on myeloid cells via Gfi-1-mediated transcriptional repression, and by triggering a TPO/CXCL1/CXCR2-dependent neutrophil motility cascade, with autophagy required for the mobilization response; receptor signaling is terminated by SOCS3-mediated K632 ubiquitination and lysosomal routing of G-CSFR; beyond hematopoiesis, G-CSF signals directly through its receptor on cardiomyocytes, dopaminergic neurons, and myoblasts via Jak/STAT3 or ERK pathways to promote cell survival and tissue regeneration, and MLKL-dependent membrane pore formation controls intracellular G-CSF release from leukemic progenitors to facilitate myeloid differentiation."},"narrative":{"teleology":[{"year":1986,"claim":"Cloning of the CSF3 gene and expression of recombinant G-CSF established it as a single-gene product sufficient for neutrophil colony stimulation and leukemia cell differentiation, resolving the molecular identity of a previously purified activity.","evidence":"cDNA cloning from CHU-2 cells, COS cell expression, CFU-GM assays, WEHI-3B differentiation assays","pmids":["3484805","2423327","2420009"],"confidence":"High","gaps":["Receptor identity unknown at this point","Signal transduction mechanism undefined","In vivo relevance of leukemia differentiation not tested"]},{"year":1993,"claim":"Determination of the four-α-helix bundle crystal structure placed G-CSF in the helical cytokine superfamily and provided a structural framework for understanding receptor engagement.","evidence":"X-ray crystallography at 2.2 Å resolution with multiple isomorphous replacement","pmids":["7685117"],"confidence":"High","gaps":["No co-crystal with receptor","Stoichiometry of ligand–receptor complex not yet resolved","Disulfide bond roles in folding vs. function not fully mapped"]},{"year":2002,"claim":"Identification of the Jak2/Lyn/c-Cbl/PI3K signaling axis downstream of G-CSFR established that proliferative signaling requires PI3K engagement beyond Jak-STAT activation alone, partitioning receptor outputs into distinct functional modules.","evidence":"Yeast two-hybrid, antisense c-Cbl knockdown in DT40-G-CSFR cells, PI3K activity and DNA synthesis assays","pmids":["12149655"],"confidence":"Medium","gaps":["Lyn–c-Cbl coupling demonstrated in a single cell system","Relative contributions of PI3K vs. ERK to proliferation unresolved","In vivo validation lacking"]},{"year":2005,"claim":"Genetic deletion of SOCS3 and STAT3 in hematopoietic cells revealed a STAT3→SOCS3 negative-feedback circuit that limits G-CSF signaling amplitude and duration, with SOCS3 loss producing sustained STAT3 activation and neutrophilia, and STAT3 loss de-repressing ERK signaling.","evidence":"Conditional Socs3-KO and Stat3-KO bone marrow, phospho-STAT3/ERK Western blot, MEK inhibitor epistasis, colony assays","pmids":["14975238","15671148"],"confidence":"High","gaps":["Mechanism of SOCS3 binding to G-CSFR not yet mapped to specific residues","Whether SOCS3 controls receptor degradation or only signal attenuation unknown"]},{"year":2005,"claim":"G-CSF was shown to mobilize hematopoietic progenitors by indirectly suppressing osteoblast function and CXCL12 expression in bone marrow, establishing the niche-disruption model of mobilization.","evidence":"G-CSFR transgenic mouse series with graded mobilization capacity, osteoblast histomorphometry, CXCL12 mRNA/protein quantification","pmids":["16037394"],"confidence":"High","gaps":["Intermediate cell type relaying signal from G-CSFR+ cells to osteoblasts unidentified","Mechanism of osteoblast suppression unknown"]},{"year":2006,"claim":"The mobilization mechanism was refined: G-CSF directly down-regulates CXCR4 on myeloid cells via the transcriptional repressor Gfi-1 (shown by ChIP at the CXCR4 promoter), while also operating a parallel TPO→CXCL1→CXCR2 cascade for neutrophil motility, revealing two complementary mobilization arms.","evidence":"Flow cytometry of CXCR4, SDF-1 migration assays, Gfi-1 ChIP at CXCR4 promoter, intravital 2-photon microscopy, CXCR2-KO and TPO-receptor-KO mice","pmids":["16537807","17596540","21224471"],"confidence":"High","gaps":["How G-CSF induces Gfi-1 expression mechanistically not defined","Whether Gfi-1 and CXCL1 pathways are redundant or additive not established"]},{"year":2006,"claim":"Receptor stoichiometry was established as a 2:2 G-CSF:G-CSFR complex with site II and site III interfaces analogous to IL-6/gp130, and G-CSF was shown to promote E-selectin ligand expression on mobilized myeloid cells by upregulating specific glycosyltransferases.","evidence":"Antibody epitope mapping, mutagenesis, receptor fragment solution binding, parallel-plate flow assay, intravital microscopy, glycosyltransferase transcript analysis","pmids":["16720384","16980970"],"confidence":"Medium","gaps":["No crystal structure of the G-CSF:G-CSFR complex","Functional contribution of each glycosyltransferase not individually tested"]},{"year":2007,"claim":"SOCS3-mediated ubiquitination of G-CSFR at K632 was identified as the mechanism routing the receptor from early endosomes to lysosomes; K632 mutation caused sustained STAT5/ERK activation and disrupted the proliferation-to-differentiation switch, connecting receptor trafficking to lineage fate decisions.","evidence":"K632 point mutagenesis, endosomal fractionation, ubiquitination assays, phospho-STAT5/ERK Western blot, myeloid differentiation assays","pmids":["17363902"],"confidence":"High","gaps":["E3 ligase recruited by SOCS3 for K632 ubiquitination not identified","Whether additional ubiquitination sites exist on G-CSFR unknown"]},{"year":2010,"claim":"Gfi-1 was positioned upstream of Ras/ERK signaling through its transcriptional target RasGRP1: Gfi1-null cells fail to activate ERK in response to G-CSF, and RasGRP1 re-expression rescues both ERK activation and neutrophil differentiation, linking the Gfi-1 transcriptional program to a specific kinase cascade.","evidence":"Gfi1-KO mice, phospho-ERK Western blot, RasGRP1 re-expression rescue, neutrophil differentiation assays","pmids":["20203268"],"confidence":"High","gaps":["Whether RasGRP1 is sufficient or only necessary for full ERK activation by G-CSF","Other Gfi-1 targets contributing to neutrophil differentiation not catalogued"]},{"year":2005,"claim":"G-CSF receptor expression and direct signaling on cardiomyocytes and dopaminergic neurons established extra-hematopoietic cytoprotective roles: Jak/STAT3 in heart and ERK/Bad/Bcl-xL in neurons, broadening G-CSF biology beyond the myeloid lineage.","evidence":"G-CSFR immunostaining on cardiomyocytes and substantia nigra neurons, dominant-negative STAT3 transgenic mice, MEK/ERK inhibitor epistasis, apoptosis assays, 6-OHDA neurotoxicity model","pmids":["15723072","16839644"],"confidence":"High","gaps":["Source of endogenous G-CSF reaching neurons in vivo not identified","Whether neuronal G-CSFR signaling is physiologically relevant or pharmacological only"]},{"year":2015,"claim":"Autophagy was identified as specifically required for G-CSF-dependent (but not AMD3100-dependent) mobilization of neutrophils and HSCs, adding a cell-autonomous metabolic requirement to the mobilization pathway.","evidence":"Autophagy-deficient mice, G-CSF vs. AMD3100 mobilization comparison, autophagy flux assays in human and mouse cells","pmids":["25788702"],"confidence":"High","gaps":["Molecular target of autophagy in mobilization (cargo identity) unknown","Whether autophagy acts on the progenitor or the niche side not determined"]},{"year":2021,"claim":"MLKL-dependent endosomal membrane pore formation was shown to control unconventional G-CSF release from leukemic progenitors, revealing a necroptosis-pathway component repurposed for cytokine secretion and myeloid differentiation.","evidence":"Mlkl-KO mice, intracellular G-CSF quantification, endosomal colocalization, membrane pore assay, myeloid differentiation assays","pmids":["34079078"],"confidence":"Medium","gaps":["Whether MLKL-dependent G-CSF release operates in non-leukemic progenitors unknown","Signal that activates MLKL for secretion vs. necroptosis not defined","Single-lab finding"]},{"year":2023,"claim":"G-CSF was identified as the principal pathogenic driver of autoinflammation in APLAID (PLCG2 p.Ser707Tyr): anti-G-CSF antibody completely reversed established disease, demonstrating that excess G-CSF is both necessary and sufficient for the inflammatory phenotype.","evidence":"APLAID knock-in mouse, anti-G-CSF antibody therapy, bone marrow transplantation, cytokine profiling, immune cell flow cytometry","pmids":["36997670"],"confidence":"High","gaps":["How PLCG2 gain-of-function drives G-CSF overproduction mechanistically not established","Non-hematopoietic cellular source of G-CSF in APLAID not identified","Relevance to human APLAID patients not yet tested therapeutically"]},{"year":null,"claim":"No crystal structure of the G-CSF:G-CSFR signaling complex exists, the molecular basis of differential pathway activation (STAT3 vs. ERK) in different cell types remains unexplained, and the intermediate cell type that relays G-CSF signals to suppress osteoblasts during mobilization is unidentified.","evidence":"","pmids":[],"confidence":"High","gaps":["Co-crystal of G-CSF:G-CSFR complex needed","Cell-type-specific pathway selection mechanism unknown","Identity of intermediate niche cell suppressing osteoblasts undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,1,9,15,20]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[8,10,11]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,1,2,27]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[1,8,11,12,13,14,18,23,25,29]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[20]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[7,8,9,10,15,17,19,26,28]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[9,15,22]}],"complexes":[],"partners":["CSF3R","JAK2","LYN","STAT3","SOCS3","GFI1","RASGRP1","MLKL"],"other_free_text":[]},"mechanistic_narrative":"CSF3 (G-CSF) is a secreted four-α-helix bundle glycoprotein that functions as the principal cytokine driving granulopoiesis, neutrophil mobilization, and emergency myelopoiesis. It signals through a homodimeric receptor (G-CSFR) in a 2:2 stoichiometry, activating Jak2/STAT3 and Lyn/c-Cbl/PI3K pathways for proliferation and differentiation, with SOCS3-mediated ubiquitination of G-CSFR at K632 routing the receptor to lysosomes as a negative-feedback brake [PMID:14975238, PMID:17363902, PMID:12149655]. G-CSF mobilizes hematopoietic stem/progenitor cells by indirectly suppressing osteoblast-derived CXCL12, directly down-regulating CXCR4 on myeloid cells through the transcriptional repressor Gfi-1, and triggering a TPO/CXCL1/CXCR2-dependent neutrophil motility cascade that requires autophagy [PMID:16037394, PMID:17596540, PMID:21224471, PMID:25788702]. Beyond hematopoiesis, G-CSF signals through its receptor on cardiomyocytes (Jak/STAT3-dependent anti-apoptosis), dopaminergic neurons (ERK-dependent survival), and regenerating myoblasts, and serves as the principal pathogenic cytokine in APLAID driven by PLCG2 gain-of-function mutations [PMID:15723072, PMID:16839644, PMID:21422169, PMID:36997670]."},"prefetch_data":{"uniprot":{"accession":"P09919","full_name":"Granulocyte colony-stimulating factor","aliases":["Pluripoietin"],"length_aa":207,"mass_kda":22.3,"function":"Granulocyte/macrophage colony-stimulating factors are cytokines that act in hematopoiesis by controlling the production, differentiation, and function of 2 related white cell populations of the blood, the granulocytes and the monocytes-macrophages. This CSF induces granulocytes","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P09919/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CSF3","classification":"Not Classified","n_dependent_lines":8,"n_total_lines":1208,"dependency_fraction":0.006622516556291391},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CSF3","total_profiled":1310},"omim":[{"mim_id":"621133","title":"OPIOID GROWTH FACTOR RECEPTOR-LIKE PROTEIN 1; OGFRL1","url":"https://www.omim.org/entry/621133"},{"mim_id":"616115","title":"FAMILIAL COLD AUTOINFLAMMATORY SYNDROME 4; FCAS4","url":"https://www.omim.org/entry/616115"},{"mim_id":"616022","title":"NEUTROPENIA, SEVERE CONGENITAL, 6, AUTOSOMAL RECESSIVE; SCN6","url":"https://www.omim.org/entry/616022"},{"mim_id":"616012","title":"JAGUNAL HOMOLOG 1; JAGN1","url":"https://www.omim.org/entry/616012"},{"mim_id":"615712","title":"OTU DEUBIQUITINASE WITH LINEAR LINKAGE SPECIFICITY; OTULIN","url":"https://www.omim.org/entry/615712"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lung","ntpm":142.1},{"tissue":"urinary bladder","ntpm":53.4}],"url":"https://www.proteinatlas.org/search/CSF3"},"hgnc":{"alias_symbol":["MGC45931"],"prev_symbol":["GCSF","G-CSF","C17orf33"]},"alphafold":{"accession":"P09919","domains":[{"cath_id":"1.20.1250.10","chopping":"42-206","consensus_level":"high","plddt":90.6168,"start":42,"end":206}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P09919","model_url":"https://alphafold.ebi.ac.uk/files/AF-P09919-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P09919-F1-predicted_aligned_error_v6.png","plddt_mean":84.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CSF3","jax_strain_url":"https://www.jax.org/strain/search?query=CSF3"},"sequence":{"accession":"P09919","fasta_url":"https://rest.uniprot.org/uniprotkb/P09919.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P09919/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P09919"}},"corpus_meta":[{"pmid":"15723072","id":"PMC_15723072","title":"G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes.","date":"2005","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15723072","citation_count":473,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26254266","id":"PMC_26254266","title":"G-CSF and GM-CSF in Neutropenia.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/26254266","citation_count":285,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25131807","id":"PMC_25131807","title":"G-CSF: From granulopoietic stimulant to bone marrow stem cell mobilizing agent.","date":"2014","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/25131807","citation_count":250,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14975238","id":"PMC_14975238","title":"SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis.","date":"2004","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/14975238","citation_count":231,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16537807","id":"PMC_16537807","title":"G-CSF down-regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16537807","citation_count":186,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12576320","id":"PMC_12576320","title":"Cell surface peptidase CD26/DPPIV mediates G-CSF mobilization of mouse progenitor cells.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12576320","citation_count":161,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19798030","id":"PMC_19798030","title":"G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis.","date":"2009","source":"Nature reviews. Rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/19798030","citation_count":134,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20237318","id":"PMC_20237318","title":"G-CSF and its receptor in myeloid malignancy.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20237318","citation_count":126,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34728120","id":"PMC_34728120","title":"G-CSF - A double edge sword in neutrophil mediated immunity.","date":"2021","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34728120","citation_count":105,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17369869","id":"PMC_17369869","title":"Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF?","date":"2007","source":"Bone marrow transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/17369869","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11823538","id":"PMC_11823538","title":"G-CSF therapy of ongoing experimental allergic encephalomyelitis via chemokine- and cytokine-based immune deviation.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11823538","citation_count":91,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12060844","id":"PMC_12060844","title":"G-CSF: function and modes of action (Review).","date":"2002","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12060844","citation_count":85,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11687616","id":"PMC_11687616","title":"Meis1a suppresses differentiation by G-CSF and promotes proliferation by SCF: potential mechanisms of cooperativity with Hoxa9 in myeloid leukemia.","date":"2001","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11687616","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33677228","id":"PMC_33677228","title":"G-CSF in tumors: Aggressiveness, tumor microenvironment and immune cell regulation.","date":"2021","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/33677228","citation_count":82,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12005202","id":"PMC_12005202","title":"Molecular aspects of anti-inflammatory action of G-CSF.","date":"2002","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/12005202","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35843375","id":"PMC_35843375","title":"Combination of G-CSF and a TLR4 inhibitor reduce inflammation and promote regeneration in a mouse model of ACLF.","date":"2022","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/35843375","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16807060","id":"PMC_16807060","title":"The role of G-CSF in adaptive immunity.","date":"2006","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/16807060","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21422169","id":"PMC_21422169","title":"G-CSF influences mouse skeletal muscle development and regeneration by stimulating myoblast proliferation.","date":"2011","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21422169","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17363902","id":"PMC_17363902","title":"Suppressor of cytokine signaling 3 controls lysosomal routing of G-CSF receptor.","date":"2007","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/17363902","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16239431","id":"PMC_16239431","title":"Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16239431","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34772606","id":"PMC_34772606","title":"G-CSF, the guardian of granulopoiesis.","date":"2021","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34772606","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16964312","id":"PMC_16964312","title":"CXCR2 ligands and G-CSF mediate PKCalpha-induced intraepidermal inflammation.","date":"2006","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/16964312","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17185469","id":"PMC_17185469","title":"Regulation of systemic and local neutrophil responses by G-CSF during pulmonary Pseudomonas aeruginosa infection.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17185469","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21685373","id":"PMC_21685373","title":"G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21685373","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24179471","id":"PMC_24179471","title":"G-CSF in Healthy Allogeneic Stem Cell Donors.","date":"2013","source":"Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie","url":"https://pubmed.ncbi.nlm.nih.gov/24179471","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19363527","id":"PMC_19363527","title":"Optimal use of G-CSF administration after hematopoietic SCT.","date":"2009","source":"Bone marrow transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/19363527","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15671148","id":"PMC_15671148","title":"Roles of Stat3 and ERK in G-CSF signaling.","date":"2005","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/15671148","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12769752","id":"PMC_12769752","title":"Pleiotropic effects of cytokines on acute myocardial infarction: G-CSF as a novel therapy for acute myocardial infarction.","date":"2003","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/12769752","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9003155","id":"PMC_9003155","title":"FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia.","date":"1996","source":"Annals of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/9003155","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17596540","id":"PMC_17596540","title":"Transcription factor Gfi-1 induced by G-CSF is a negative regulator of CXCR4 in myeloid cells.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17596540","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24416642","id":"PMC_24416642","title":"SOCS3: An essential physiological inhibitor of signaling by interleukin-6 and G-CSF family cytokines.","date":"2013","source":"JAK-STAT","url":"https://pubmed.ncbi.nlm.nih.gov/24416642","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9509971","id":"PMC_9509971","title":"Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trial.","date":"1998","source":"Bone marrow transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/9509971","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32242230","id":"PMC_32242230","title":"Cancer-associated adipocyte-derived G-CSF promotes breast cancer malignancy via Stat3 signaling.","date":"2020","source":"Journal of molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/32242230","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24707817","id":"PMC_24707817","title":"G-CSF: filgrastim, lenograstim and biosimilars.","date":"2014","source":"Expert opinion on biological therapy","url":"https://pubmed.ncbi.nlm.nih.gov/24707817","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8847044","id":"PMC_8847044","title":"Combination treatment of advanced HCV associated liver disease with interferon and G-CSF.","date":"1995","source":"Hepato-gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/8847044","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25804941","id":"PMC_25804941","title":"Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor.","date":"2015","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/25804941","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15135666","id":"PMC_15135666","title":"G-CSF treatment increases side population cell infiltration after myocardial infarction in mice.","date":"2004","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/15135666","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16418824","id":"PMC_16418824","title":"Effects of G-CSF on left ventricular remodeling and heart failure after acute myocardial infarction.","date":"2006","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/16418824","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16839644","id":"PMC_16839644","title":"G-CSF protects dopaminergic neurons from 6-OHDA-induced toxicity via the ERK pathway.","date":"2006","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/16839644","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21292774","id":"PMC_21292774","title":"G-CSF improves murine G6PC3-deficient neutrophil function by modulating apoptosis and energy homeostasis.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21292774","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16980970","id":"PMC_16980970","title":"G-CSF induces E-selectin ligand expression on human myeloid cells.","date":"2006","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16980970","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20203268","id":"PMC_20203268","title":"The transcription factor Gfi1 regulates G-CSF signaling and neutrophil development through the Ras activator RasGRP1.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20203268","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9015212","id":"PMC_9015212","title":"Increased G-CSF responsiveness of bone marrow cells from hematopoietic cell phosphatase deficient viable motheaten mice.","date":"1997","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/9015212","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16435574","id":"PMC_16435574","title":"Effects of whole-body gamma irradiation and 5-androstenediol administration on serum G-CSF.","date":"2005","source":"Immunopharmacology and immunotoxicology","url":"https://pubmed.ncbi.nlm.nih.gov/16435574","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25788702","id":"PMC_25788702","title":"Autophagy is required for stem cell mobilization by G-CSF.","date":"2015","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25788702","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9374735","id":"PMC_9374735","title":"Hemorrhagic shock induces G-CSF expression in bronchial epithelium.","date":"1997","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/9374735","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33389706","id":"PMC_33389706","title":"Neuroprotection through G-CSF: recent advances and future viewpoints.","date":"2021","source":"Pharmacological reports : PR","url":"https://pubmed.ncbi.nlm.nih.gov/33389706","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34763974","id":"PMC_34763974","title":"Immunomodulatory effects of G-CSF in cancer: Therapeutic implications.","date":"2021","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34763974","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24844175","id":"PMC_24844175","title":"Stem cells and G-CSF for treating neuroinflammation in traumatic brain injury: aging as a comorbidity factor.","date":"2014","source":"Journal of neurosurgical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24844175","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21745453","id":"PMC_21745453","title":"Can G-CSF cause leukemia in hematopoietic stem cell donors?","date":"2011","source":"Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/21745453","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23669105","id":"PMC_23669105","title":"Antidiabetic gliptins in combination with G-CSF enhances myocardial function and survival after acute myocardial infarction.","date":"2013","source":"International journal of cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/23669105","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26538529","id":"PMC_26538529","title":"Role of G-CSF in monophosphoryl lipid A-mediated augmentation of neutrophil functions after burn injury.","date":"2015","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/26538529","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18495331","id":"PMC_18495331","title":"AMD3100 synergizes with G-CSF to mobilize repopulating stem cells in Fanconi anemia knockout mice.","date":"2008","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/18495331","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12672695","id":"PMC_12672695","title":"Impaired neutrophil maturation in truncated murine G-CSF receptor-transgenic mice.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12672695","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16720384","id":"PMC_16720384","title":"The interaction of G-CSF with its receptor.","date":"2006","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/16720384","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10773052","id":"PMC_10773052","title":"Functional characteristics of neutrophils collected and stored after administration of G-CSF.","date":"2000","source":"Transfusion","url":"https://pubmed.ncbi.nlm.nih.gov/10773052","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15894583","id":"PMC_15894583","title":"Identification of CCR2, flotillin, and gp49B genes as new G-CSF targets during neutrophilic differentiation.","date":"2005","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/15894583","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16737933","id":"PMC_16737933","title":"Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF.","date":"2006","source":"Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/16737933","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28320832","id":"PMC_28320832","title":"G-CSF Receptor Blockade Ameliorates Arthritic Pain and Disease.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/28320832","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18393854","id":"PMC_18393854","title":"Granulocyte colony-stimulating factor (G-CSF) for cardio- and cerebrovascular regenerative applications.","date":"2008","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18393854","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33737338","id":"PMC_33737338","title":"Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma.","date":"2021","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33737338","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26524416","id":"PMC_26524416","title":"G-CSF promotes autophagy and reduces neural tissue damage after spinal cord injury in mice.","date":"2015","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26524416","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20382196","id":"PMC_20382196","title":"Serum IL-7 and G-CSF in major depressive disorder.","date":"2010","source":"Progress in neuro-psychopharmacology & biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/20382196","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9681250","id":"PMC_9681250","title":"G-CSF production in human bladder cancer and its ability to promote autocrine growth: a review.","date":"1998","source":"Cytokines, cellular & molecular therapy","url":"https://pubmed.ncbi.nlm.nih.gov/9681250","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26482176","id":"PMC_26482176","title":"Translating G-CSF as an Adjunct Therapy to Stem Cell Transplantation for Stroke.","date":"2015","source":"Translational stroke research","url":"https://pubmed.ncbi.nlm.nih.gov/26482176","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30988118","id":"PMC_30988118","title":"Trauma Induces Emergency Hematopoiesis through IL-1/MyD88-Dependent Production of G-CSF.","date":"2019","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/30988118","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21358682","id":"PMC_21358682","title":"G-CSF downregulates natural killer cell-mediated cytotoxicity in donors for hematopoietic SCT.","date":"2011","source":"Bone marrow transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/21358682","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9028513","id":"PMC_9028513","title":"G-CSF stimulated donor granulocyte collections for prophylaxis and therapy of neutropenic sepsis.","date":"1996","source":"Australian and New Zealand journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9028513","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26114754","id":"PMC_26114754","title":"LPS-Induced G-CSF Expression in Macrophages Is Mediated by ERK2, but Not ERK1.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26114754","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31811421","id":"PMC_31811421","title":"Plinabulin ameliorates neutropenia induced by multiple chemotherapies through a mechanism distinct from G-CSF therapies.","date":"2019","source":"Cancer chemotherapy and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31811421","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9332315","id":"PMC_9332315","title":"Effects of in vivo administration of G-CSF on neutrophil and eosinophil adhesion.","date":"1997","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/9332315","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8582455","id":"PMC_8582455","title":"Serum concentration of endogenous G-CSF in women during the menstrual cycle and pregnancy.","date":"1995","source":"European journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/8582455","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22846180","id":"PMC_22846180","title":"Pharmacokinetic and -dynamic modelling of G-CSF derivatives in humans.","date":"2012","source":"Theoretical biology & medical modelling","url":"https://pubmed.ncbi.nlm.nih.gov/22846180","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19275877","id":"PMC_19275877","title":"Potentiation of angiogenesis and regeneration by G-CSF after sciatic nerve crush injury.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19275877","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12149655","id":"PMC_12149655","title":"Repression of c-Cbl leads to enhanced G-CSF Jak-STAT signaling without increased cell proliferation.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12149655","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34049929","id":"PMC_34049929","title":"G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment.","date":"2021","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34049929","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21623923","id":"PMC_21623923","title":"G-CSF enhances the proliferation and mobilization, but not the maturation rate, of murine myeloid cells.","date":"2011","source":"European journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/21623923","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28881590","id":"PMC_28881590","title":"Upregulation of microRNA-125b by G-CSF promotes metastasis in colorectal cancer.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28881590","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7543246","id":"PMC_7543246","title":"Receptor-mediated clearance of G-CSF derivative nartograstim in bone marrow of rats.","date":"1995","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/7543246","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29784961","id":"PMC_29784961","title":"Sarcodon imbricatus polysaccharides improve mouse hematopoietic function after cyclophosphamide-induced damage via G-CSF mediated JAK2/STAT3 pathway.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29784961","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23276911","id":"PMC_23276911","title":"Scratching the surface: signaling and routing dynamics of the CSF3 receptor.","date":"2013","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/23276911","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24073859","id":"PMC_24073859","title":"New G-CSF agonists for neutropenia therapy.","date":"2013","source":"Expert opinion on investigational drugs","url":"https://pubmed.ncbi.nlm.nih.gov/24073859","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29352287","id":"PMC_29352287","title":"IFNγ inhibits G-CSF induced neutrophil expansion and invasion of the CNS to prevent viral encephalitis.","date":"2018","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/29352287","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1725961","id":"PMC_1725961","title":"Alternative forms of the human G-CSF receptor function in growth signal transduction.","date":"1991","source":"The New biologist","url":"https://pubmed.ncbi.nlm.nih.gov/1725961","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6802860","id":"PMC_6802860","title":"G-CSF: its relationship to leukemia differentiation-inducing activity and other hemopoietic regulators.","date":"1982","source":"Journal of cellular physiology. Supplement","url":"https://pubmed.ncbi.nlm.nih.gov/6802860","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9755100","id":"PMC_9755100","title":"Alveolar type II-like cells release G-CSF as neutrophil chemotactic activity.","date":"1998","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/9755100","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36997670","id":"PMC_36997670","title":"G-CSF drives autoinflammation in APLAID.","date":"2023","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36997670","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30719047","id":"PMC_30719047","title":"Pretreatment with G-CSF Could Enhance the Antifibrotic Effect of BM-MSCs on Pulmonary Fibrosis.","date":"2019","source":"Stem cells international","url":"https://pubmed.ncbi.nlm.nih.gov/30719047","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17127394","id":"PMC_17127394","title":"Src kinases in G-CSF receptor signaling.","date":"2007","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/17127394","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32092138","id":"PMC_32092138","title":"Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield.","date":"2020","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/32092138","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22890921","id":"PMC_22890921","title":"Hematopoietic stem cell mobilization with agents other than G-CSF.","date":"2012","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/22890921","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17692407","id":"PMC_17692407","title":"G-CSF after myocardial infarction accelerates angiogenesis and reduces fibrosis in swine.","date":"2007","source":"International journal of cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/17692407","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26827874","id":"PMC_26827874","title":"Mobilization of hematopoietic stem cells with highest self-renewal by G-CSF precedes clonogenic cell mobilization peak.","date":"2016","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/26827874","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7507758","id":"PMC_7507758","title":"The role of stem cell factor in mobilization of peripheral blood progenitor cells: synergy with G-CSF.","date":"1993","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/7507758","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30283148","id":"PMC_30283148","title":"Current use of biosimilar G-CSF for haematopoietic stem cell mobilisation.","date":"2018","source":"Bone marrow transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/30283148","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20354107","id":"PMC_20354107","title":"Systemic levels of G-CSF and interleukin-6 determine the angiogenic potential of bone marrow resident monocytes.","date":"2010","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/20354107","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22890920","id":"PMC_22890920","title":"Hematopoietic stem cell mobilization with G-CSF.","date":"2012","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/22890920","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1692536","id":"PMC_1692536","title":"Antagonistic effects of interleukin 6 and G-CSF in the later stage of human granulopoiesis in vitro.","date":"1990","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/1692536","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16979158","id":"PMC_16979158","title":"Effects of G-CSF on cardiac remodeling and arterial hyperplasia in rats.","date":"2006","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16979158","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34079078","id":"PMC_34079078","title":"MLKL promotes cellular differentiation in myeloid leukemia by facilitating the release of G-CSF.","date":"2021","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/34079078","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2420009","id":"PMC_2420009","title":"Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells.","date":"1986","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/2420009","citation_count":1334,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3484805","id":"PMC_3484805","title":"Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor.","date":"1986","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/3484805","citation_count":808,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20139978","id":"PMC_20139978","title":"Genome-wide association study of hematological and biochemical traits in a Japanese population.","date":"2010","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20139978","citation_count":406,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16037394","id":"PMC_16037394","title":"G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16037394","citation_count":403,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12034575","id":"PMC_12034575","title":"Interleukin-17 stimulates the expression of interleukin-8, growth-related oncogene-alpha, and granulocyte-colony-stimulating factor by human airway epithelial cells.","date":"2002","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12034575","citation_count":243,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2423327","id":"PMC_2423327","title":"The chromosomal gene structure and two mRNAs for human granulocyte colony-stimulating factor.","date":"1986","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/2423327","citation_count":228,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17703412","id":"PMC_17703412","title":"Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes.","date":"2007","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/17703412","citation_count":223,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7685117","id":"PMC_7685117","title":"The structure of granulocyte-colony-stimulating factor and its relationship to other growth factors.","date":"1993","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7685117","citation_count":213,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18537187","id":"PMC_18537187","title":"Granulocyte-colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial.","date":"2008","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/18537187","citation_count":189,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12676791","id":"PMC_12676791","title":"G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune diseases.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12676791","citation_count":176,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21224471","id":"PMC_21224471","title":"G-CSF-mediated thrombopoietin release triggers neutrophil motility and mobilization from bone marrow via induction of Cxcr2 ligands.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21224471","citation_count":175,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21079612","id":"PMC_21079612","title":"Mechanisms of G-CSF-mediated hematopoietic stem and progenitor mobilization.","date":"2010","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/21079612","citation_count":172,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19913121","id":"PMC_19913121","title":"Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.","date":"2009","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19913121","citation_count":164,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12009905","id":"PMC_12009905","title":"Aggregation of granulocyte colony stimulating factor under physiological conditions: characterization and thermodynamic inhibition.","date":"2002","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12009905","citation_count":151,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18952897","id":"PMC_18952897","title":"Serum amyloid A induces G-CSF expression and neutrophilia via Toll-like receptor 2.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18952897","citation_count":140,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20435882","id":"PMC_20435882","title":"Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20435882","citation_count":140,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26666576","id":"PMC_26666576","title":"The significance of G-CSF expression and myeloid-derived suppressor cells in the chemoresistance of uterine cervical cancer.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26666576","citation_count":133,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16735597","id":"PMC_16735597","title":"G-CSF and AMD3100 mobilize monocytes into the blood that stimulate angiogenesis in vivo through a paracrine mechanism.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16735597","citation_count":118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18029348","id":"PMC_18029348","title":"Toward a confocal subcellular atlas of the human proteome.","date":"2007","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/18029348","citation_count":114,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18219369","id":"PMC_18219369","title":"Differential constitutive and cytokine-modulated expression of human Toll-like receptors in primary neutrophils, monocytes, and macrophages.","date":"2008","source":"International journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/18219369","citation_count":113,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16912178","id":"PMC_16912178","title":"Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16912178","citation_count":111,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1692828","id":"PMC_1692828","title":"Structural characterization of natural and recombinant human granulocyte colony-stimulating factors.","date":"1990","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1692828","citation_count":109,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11877288","id":"PMC_11877288","title":"Effects of administration of progenipoietin 1, Flt-3 ligand, granulocyte colony-stimulating factor, and pegylated granulocyte-macrophage colony-stimulating factor on dendritic cell subsets in mice.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11877288","citation_count":106,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15616013","id":"PMC_15616013","title":"Treatment with granulocyte colony-stimulating factor prevents diabetes in NOD mice by recruiting plasmacytoid dendritic cells and functional CD4(+)CD25(+) regulatory T-cells.","date":"2005","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/15616013","citation_count":105,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33393205","id":"PMC_33393205","title":"M2 macrophage-derived G-CSF promotes trophoblasts EMT, invasion and migration via activating PI3K/Akt/Erk1/2 pathway to mediate normal pregnancy.","date":"2021","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33393205","citation_count":104,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16051386","id":"PMC_16051386","title":"Endogenous G-CSF and CD34+ cell mobilization after acute myocardial infarction.","date":"2005","source":"International journal of cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/16051386","citation_count":103,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":46781,"output_tokens":5496,"usd":0.111392},"stage2":{"model":"claude-opus-4-6","input_tokens":9062,"output_tokens":4177,"usd":0.224603},"total_usd":0.715877,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":60975,"output_tokens":7844,"usd":0.150292},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":11817,"output_tokens":3759,"usd":0.22959}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2005,\n      \"finding\": \"G-CSF acts directly on cardiomyocytes via G-CSF receptor expression, activating the Jak/Stat pathway; dominant-negative Stat3 overexpression in cardiomyocytes abolished the cardioprotective effects, demonstrating that Stat3 is required for G-CSF-mediated anti-apoptotic signaling in the heart.\",\n      \"method\": \"Dominant-negative Stat3 transgenic mice, in vivo myocardial infarction model, immunohistochemistry, apoptosis assays\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with dominant-negative mutant clearly links G-CSF/G-CSFR to Jak/Stat3 pathway in cardiomyocytes; multiple orthogonal methods in single study\",\n      \"pmids\": [\"15723072\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"SOCS3 is a key negative regulator of G-CSF (CSF3) signaling in myeloid cells; SOCS3-deficient myeloid cells show prolonged STAT3 activation and enhanced cellular responses to G-CSF including increased proliferation, survival, and cloning frequency.\",\n      \"method\": \"Conditional Socs3 gene deletion in hematopoietic cells (Cre-lox), in vitro G-CSF stimulation assays, in vivo G-CSF treatment of knockout mice\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined cellular phenotypes, replicated across in vitro and in vivo settings\",\n      \"pmids\": [\"14975238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"SOCS3 controls lysosomal routing of the G-CSF receptor (CSF3R) through ubiquitination of a juxtamembrane lysine residue (K632); mutation of K632 causes accumulation of G-CSFR in early endosomes and leads to sustained activation of STAT5 and ERK, altering the proliferation/differentiation balance of myeloid progenitors.\",\n      \"method\": \"Site-directed mutagenesis of G-CSFR K632, receptor routing assays, endosomal fractionation, signaling assays in myeloid progenitors\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis combined with receptor routing and functional signaling assays; first demonstration of SOCS-mediated ubiquitination and routing of a cytokine receptor\",\n      \"pmids\": [\"17363902\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"G-CSF down-regulates CXCR4 expression selectively on bone marrow myeloid lineage cells, reducing their responsiveness to SDF-1 and thereby promoting their mobilization from bone marrow to peripheral blood.\",\n      \"method\": \"Flow cytometry of murine Gr1+ cells treated with G-CSF in vitro and in vivo, attachment and migration assays with SDF-1\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal in vitro and in vivo evidence, lineage-specific effect demonstrated with multiple functional assays\",\n      \"pmids\": [\"16537807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"G-CSF induces expression of the transcriptional repressor Gfi-1, which binds DNA sequences upstream of the CXCR4 gene and represses CXCR4 expression in myeloid lineage cells, reducing their response to SDF-1 and promoting their release from bone marrow.\",\n      \"method\": \"In vitro and in vivo G-CSF treatment, chromatin immunoprecipitation (ChIP), reporter assays, Gfi-1 overexpression and knockdown\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP demonstrates direct Gfi-1 binding to CXCR4 promoter; multiple orthogonal methods\",\n      \"pmids\": [\"17596540\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The transcription factor Gfi1 promotes RasGRP1 expression, which is required for G-CSF signaling through the Ras/MEK/Erk pathway; Gfi1-null myeloid cells are selectively defective in G-CSF-induced Erk1/2 activation and fail to differentiate into neutrophils, and RasGRP1 re-expression rescues this defect.\",\n      \"method\": \"Gfi1-knockout mice, G-CSF stimulation assays, Erk activation assays, rescue by RasGRP1 re-expression in Gfi1-deficient cells\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with rescue experiment; multiple orthogonal approaches\",\n      \"pmids\": [\"20203268\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Stat3 functions as a negative regulator of G-CSF signaling by inducing SOCS3 expression; in Stat3-null hematopoietic cells, SOCS3 is barely expressed and G-CSF stimulation leads to sustained ERK1/2 activation that drives enhanced proliferation, which is blocked by MEK1 inhibitor.\",\n      \"method\": \"Stat3-conditional knockout mice in hematopoietic cells, G-CSF stimulation assays, MEK1 inhibitor experiments, SOCS3 expression analysis\",\n      \"journal\": \"Stem cells\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with pharmacological inhibitor confirmation; mechanistic pathway placement established\",\n      \"pmids\": [\"15671148\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"G-CSF protects dopaminergic neurons from 6-OHDA-induced toxicity via ERK activation (not Jak/Stat), which leads to Bad phosphorylation, restoration of Bcl-xL, and inhibition of caspase-3 activation; ERK inhibition abrogated G-CSF-mediated neuroprotection.\",\n      \"method\": \"6-OHDA neurotoxicity model in mesencephalic cultures, ERK inhibitor treatment, Western blots for signaling intermediates, caspase-3 activity assay\",\n      \"journal\": \"Neurobiology of aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological inhibition of ERK combined with multiple signaling readouts in a single study\",\n      \"pmids\": [\"16839644\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"c-Cbl directly couples Lyn to PI 3-kinase in G-CSF receptor signaling; c-Cbl uncoupling from PI 3-kinase (c-CblY731F mutant) inhibits G-CSF-induced proliferative signaling, while antisense inhibition of c-Cbl enhances Jak-STAT activation but decreases PI 3-kinase activity and DNA synthesis.\",\n      \"method\": \"Yeast two-hybrid, antisense inhibition of c-Cbl, c-CblY731F mutant expression, PI 3-kinase activity assays, DNA synthesis assays in DT40GR cells\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple biochemical assays with complementary genetic and molecular approaches in a single study\",\n      \"pmids\": [\"12149655\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"The cytoplasmic domain of the G-CSF receptor (first 96 amino acids) is required for signal transduction; deletion of this region abolishes G-CSF-induced growth signaling, and both alternatively-spliced receptor isoforms are functional.\",\n      \"method\": \"Transfection of wild-type and cytoplasmic domain deletion mutant G-CSFR cDNAs into IL-3-dependent and IL-6-dependent murine cell lines, growth assays, ligand binding assays\",\n      \"journal\": \"The New biologist\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis/deletion with functional reconstitution in heterologous cell systems; clearly establishes cytoplasmic domain requirement\",\n      \"pmids\": [\"1725961\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The G-CSF receptor complex has 2:2 stoichiometry (two binding sites on both ligand and receptor), equivalent to site II and site III of the IL-6 receptor complex; structural model based on crystallized ligand-binding domain fragment in complex with G-CSF and mutagenesis/antibody mapping data.\",\n      \"method\": \"Crystal structure of partial ligand-binding domain with G-CSF, neutralizing antibody mapping, solution binding studies with receptor fragments, mutagenesis\",\n      \"journal\": \"Frontiers in bioscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — structural data combined with mutagenesis and binding studies; single review/analysis paper\",\n      \"pmids\": [\"16720384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CD26/DPPIV cleaves CXCL12 at its position-2 proline; CD26 inhibition enhances migration of hematopoietic progenitors to CXCL12 and reduces G-CSF-induced progenitor mobilization in vivo, indicating that CD26-mediated CXCL12 cleavage is a mechanism of G-CSF-induced mobilization.\",\n      \"method\": \"Chemotaxis assays with truncated CXCL12, CD26 inhibitor treatment, in vivo mobilization assays in mice\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional in vitro and in vivo assays with pharmacological inhibitors and truncated ligand\",\n      \"pmids\": [\"12576320\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Truncation mutations in the cytoplasmic region of G-CSFR impair neutrophil maturation and cause myeloid progenitor hypersensitivity to G-CSF; transgenic mice expressing truncated G-CSFR show decreased peripheral neutrophils, increased immature myeloid cells in bone marrow (maturation arrest), and impaired bacterial infection resistance.\",\n      \"method\": \"Transgenic mice expressing truncated G-CSFR equivalents to human SCN mutations, in vitro bone marrow colony assays under G-CSF stimulation, infection challenge\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — transgenic mouse model with defined receptor mutations, multiple readouts including in vitro and in vivo\",\n      \"pmids\": [\"12672695\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"G-CSF activates autophagy in neutrophils and hematopoietic stem cells; G-CSF-induced neutrophil and HSC mobilization is impaired in the absence of autophagy, while direct HSC mobilization by the CXCR4 antagonist AMD3100 is autophagy-independent.\",\n      \"method\": \"Autophagy-deficient mouse models, G-CSF and AMD3100 mobilization assays, autophagy quantification in mouse and human cells\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function with defined cellular phenotype, mechanism dissected by comparison with AMD3100\",\n      \"pmids\": [\"25788702\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"MLKL facilitates G-CSF release from leukemic progenitor cells by controlling membrane permeabilization; MLKL associates with early endosomes and controls G-CSF secretion from intracellular storage via plasma membrane pore formation, and loss of MLKL impairs myeloid differentiation in AML.\",\n      \"method\": \"Mlkl-knockout mice, G-CSF secretion assays, endosomal co-localization, membrane permeabilization assays, AML differentiation assays\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with multiple mechanistic assays; novel finding linking MLKL to G-CSF secretion\",\n      \"pmids\": [\"34079078\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LPS-induced G-CSF expression in macrophages is mediated specifically by ERK2 (not ERK1) via chromatin remodeling at the G-CSF promoter; ERK2 promotes C/EBPβ- and NF-κB-dependent transcription of G-CSF by controlling chromatin accessibility at the promoter.\",\n      \"method\": \"shRNA knockdown of ERK1 vs ERK2, G-CSF promoter reporter assays, ChIP for NF-κB and C/EBPβ, DNase I accessibility assay, MEK1/2 inhibitor (U0126) treatment\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP and chromatin remodeling assays combined with isoform-specific knockdown; single study\",\n      \"pmids\": [\"26114754\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"G-CSF influences skeletal muscle development and regeneration by directly stimulating myoblast proliferation via G-CSF receptor expressed on myoblasts; G-CSFR-knockout mice show markedly impaired muscle regeneration, and neutralizing G-CSF with blocking antibody impairs regeneration.\",\n      \"method\": \"G-CSFR-knockout mice, anti-G-CSF blocking antibody, GFP-chimeric mouse tracking, immunohistochemistry for G-CSFR expression in myoblasts\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO and antibody neutralization with defined phenotypic readouts; replicated across developmental and injury contexts\",\n      \"pmids\": [\"21422169\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"G-CSF induces expression of E-selectin ligands (HCELL and an ~65-kDa ligand) on myeloid cells by upregulating glycosyltransferases (ST3GalIV, FucT-IV, FucT-VII), enhancing myeloid cell adhesion to inflamed endothelium under physiologic flow; enzymatic treatments confirmed these ligands mediate the adhesion.\",\n      \"method\": \"Parallel plate flow assays, intravital microscopy, enzymatic treatments, transcript analysis of glycosyltransferases, in vitro G-CSF treatment of bone marrow cells\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (biochemical, functional flow assays, in vivo microscopy); strong mechanistic evidence\",\n      \"pmids\": [\"16980970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"G-CSF is the key driver of autoinflammation in APLAID (PLCG2 mutation disease); anti-G-CSF antibody treatment completely reversed established disease in APLAID mice, normalized myelopoiesis, and rebounded lymphocyte numbers; bone marrow transplantation also rescued the disease with concomitant reduction of G-CSF production predominantly from non-hematopoietic cells.\",\n      \"method\": \"APLAID knock-in mouse model, anti-G-CSF antibody treatment, bone marrow transplantation, cytokine analysis\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic mouse model with antibody intervention and BMT rescue; multiple orthogonal methods, strong evidence for G-CSF as disease driver\",\n      \"pmids\": [\"36997670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"G-CSF receptor in bone marrow mediates nonlinear (saturable) clearance of G-CSF; receptor downregulation after excess G-CSF reduces tissue uptake clearance, while upregulation following repeated dosing increases it, demonstrating receptor-mediated endocytosis as the primary elimination mechanism.\",\n      \"method\": \"In vivo pharmacokinetic studies in rats with radiolabeled G-CSF, receptor binding studies on isolated bone marrow cells, cyclophosphamide-treated and repeat-dose models\",\n      \"journal\": \"The American journal of physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — quantitative in vivo and in vitro receptor binding studies correlating pharmacokinetics with receptor density\",\n      \"pmids\": [\"7543246\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CSF3R (G-CSFR) signaling involves receptor internalization, ubiquitination, and intracellular routing through signaling endosomes; interactions between signaling endosomes and the endoplasmic reticulum modulate signal amplitude and duration, contributing to the balanced proliferation-then-differentiation output of G-CSF/CSF3R signaling.\",\n      \"method\": \"Review integrating receptor routing assays, ubiquitination studies, redox-regulated phosphatase activity assays at endosomes\",\n      \"journal\": \"Frontiers in bioscience (Landmark edition)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — mechanistic review synthesizing experimental findings from multiple studies; some original data referenced\",\n      \"pmids\": [\"23276911\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Tissue injury induces emergency hematopoiesis through an IL-1/MyD88-dependent signaling pathway that drives G-CSF production; G-CSF then expands hematopoietic progenitors and increases myeloid-skewed progenitor frequency.\",\n      \"method\": \"Polytrauma mouse model, IL-1 receptor and MyD88 knockout mice, G-CSF measurement, hematopoietic progenitor flow cytometry\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO epistasis establishing pathway position; single study\",\n      \"pmids\": [\"30988118\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"IFNγ suppresses G-CSF signaling by increasing SOCS3 expression in neutrophils, resulting in apoptosis; G-CSF depletion (but not GM-CSF depletion) in IFNγ-deficient mice restored neutrophil apoptosis and T-cell IL-10 production, preventing fatal viral encephalitis.\",\n      \"method\": \"IFNγ-knockout mice, G-CSF and GM-CSF neutralization antibodies, neutrophil apoptosis assays, SOCS3 expression analysis\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis (IFNγ KO) plus cytokine neutralization with multiple phenotypic and molecular readouts\",\n      \"pmids\": [\"29352287\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CSF3 (G-CSF) binds its homodimeric receptor (CSF3R/G-CSFR) in a 2:2 complex, activating non-receptor tyrosine kinases Jak2 and Lyn, which signal through STAT3/STAT5, ERK1/2 (via Gfi1-dependent RasGRP1 and c-Cbl-coupled PI3K), and Akt pathways to drive myeloid progenitor proliferation followed by neutrophil differentiation; SOCS3 (induced by STAT3) and receptor ubiquitination at K632 terminate signaling by routing the receptor to lysosomes; G-CSF also promotes myeloid cell egress from bone marrow by inducing Gfi-1-mediated transcriptional repression of CXCR4 and CD26-mediated cleavage of SDF-1, and activates autophagy as a required step in HSC mobilization, while directly promoting survival of cardiomyocytes, dopaminergic neurons, and myoblasts through receptor-mediated activation of context-dependent signaling branches.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1986,\n      \"finding\": \"The gene encoding human G-CSF (CSF3) was cloned from a squamous carcinoma cell line (CHU-2); the cDNA expressed in COS cells produced a protein with authentic G-CSF activity. Two mRNA isoforms arise from alternative splicing of the second intron. The mature secreted protein is O-glycosylated (Thr-133) with MW ~19,600 Da.\",\n      \"method\": \"cDNA cloning, COS cell expression, competitive radioligand binding assay, biochemical characterization\",\n      \"journal\": \"Nature / EMBO Journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original cloning and expression with functional validation, independently replicated (two papers)\",\n      \"pmids\": [\"3484805\", \"2423327\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1986,\n      \"finding\": \"Recombinant human G-CSF (expressed in E. coli) supports neutrophil colony formation (CFU-GM assay), induces terminal differentiation of WEHI-3B(D+) myelomonocytic leukemia cells, and supports early erythroid and mixed colonies. Leukemic cells bearing G-CSF receptors (demonstrated by 125I-labeled ligand binding) undergo terminal differentiation to macrophages and granulocytes.\",\n      \"method\": \"Recombinant protein expression, CFU-GM colony assay, competitive radioligand binding, cell differentiation assays\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted recombinant protein with multiple orthogonal functional assays\",\n      \"pmids\": [\"2420009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Natural and recombinant human G-CSF both contain a free Cys-17 and two intramolecular disulfide bonds (Cys-36/Cys-42 and Cys-64/Cys-74), with O-glycosylation at Thr-133; both forms exhibit equivalent biological activity in vitro and in vivo.\",\n      \"method\": \"Protein purification, amino acid sequencing, biochemical disulfide mapping, CD spectroscopy, colony-forming and in vivo bioassays\",\n      \"journal\": \"Journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct structural and biochemical characterization of purified natural and recombinant protein\",\n      \"pmids\": [\"1692828\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Two alternatively spliced forms of the G-CSF receptor (G-CSFR) both transduce G-CSF proliferative signals when expressed in IL-3-dependent BAF/BO3 or IL-6-dependent B9 cells. A cytoplasmic-domain deletion mutant fails to confer G-CSF responsiveness, indicating that the first 96 amino acids of the cytoplasmic domain are required for signal transduction.\",\n      \"method\": \"cDNA transfection into cytokine-dependent cell lines, growth assays, radioligand binding\",\n      \"journal\": \"The New biologist\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution of receptor signaling with deletion mutagenesis defining essential cytoplasmic domain\",\n      \"pmids\": [\"1725961\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"X-ray crystal structure of recombinant human G-CSF at 2.2 Å resolution reveals a four-α-helix bundle with up-up-down-down connectivity, placing it in the same structural superfamily as growth hormone, GM-CSF, interferon-β, IL-2, and IL-4, suggesting a conserved receptor-binding mechanism.\",\n      \"method\": \"X-ray crystallography (multiple isomorphous replacement, 2.2 Å resolution)\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with full refinement at high resolution\",\n      \"pmids\": [\"7685117\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"G-CSF is cleared from the body primarily via receptor-mediated endocytosis in bone marrow; elimination is saturable with a Km (~107 pM) matching the receptor dissociation constant (Kd), and receptor downregulation after excess G-CSF reduces tissue uptake clearance, which recovers as receptors are replenished.\",\n      \"method\": \"Steady-state infusion pharmacokinetics in rats, 125I-labeled ligand tissue uptake assays, cyclophosphamide and repeated-dosing receptor modulation experiments\",\n      \"journal\": \"The American journal of physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — quantitative in vivo pharmacokinetic-receptor binding analysis with multiple experimental conditions\",\n      \"pmids\": [\"7543246\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"rhG-CSF aggregation under physiological conditions (pH 6.9, 37°C) proceeds through a reversible dimer intermediate that does not itself participate in irreversible aggregation; sucrose stabilizes the native monomeric state by thermodynamic preferential exclusion, reducing the population of structurally expanded intermediates that seed aggregation.\",\n      \"method\": \"Biochemical aggregation assays, hydrogen-deuterium exchange, thermal unfolding, sucrose stabilization experiments\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal biophysical methods establishing mechanism of aggregation\",\n      \"pmids\": [\"12009905\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"G-CSF receptor (G-CSFR) engages the Jak2 and Lyn non-receptor tyrosine kinases upon ligand binding. Lyn phosphorylates c-Cbl, which couples to PI3-kinase; the c-Cbl/PI3-kinase pathway is required for G-CSF-induced proliferative (DNA synthesis) signaling, whereas Jak-STAT activation alone is insufficient for proliferation.\",\n      \"method\": \"Yeast two-hybrid (Lyn–c-Cbl–PI3K coupling), antisense knockdown of c-Cbl in DT40 cells expressing G-CSFR, Jak-STAT and PI3-kinase activity assays, DNA synthesis measurement\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — epistasis established in cell model with multiple signaling readouts, single lab\",\n      \"pmids\": [\"12149655\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"SOCS3 is a key negative regulator of G-CSF signaling in myeloid cells: hematopoietic-specific Socs3-knockout mice display prolonged STAT3 activation and enhanced cellular responses to G-CSF (increased cloning frequency, survival, proliferation, neutrophilia, and progenitor mobilization), demonstrating that SOCS3 normally limits the amplitude and duration of G-CSF/STAT3 signaling.\",\n      \"method\": \"Conditional Socs3 gene knockout (hematopoietic cells), in vitro G-CSF stimulation assays, in vivo G-CSF injection, phospho-STAT3 Western blot\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function with multiple orthogonal in vitro and in vivo readouts, well-cited\",\n      \"pmids\": [\"14975238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"G-CSF acts directly on cardiomyocytes (which express G-CSF receptor) and activates the Jak/STAT3 pathway; this signaling induces anti-apoptotic proteins, reduces cardiomyocyte and endothelial cell apoptosis, and increases vascularization after myocardial infarction. Overexpression of dominant-negative STAT3 in cardiomyocytes abolishes all these protective effects.\",\n      \"method\": \"Dominant-negative STAT3 transgenic mice, G-CSF receptor immunostaining on cardiomyocytes, Jak/STAT phosphorylation assays, apoptosis assays, cardiac function measurement, vascularization histology\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic dominant-negative rescue approach with multiple orthogonal readouts, highly cited\",\n      \"pmids\": [\"15723072\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Stat3 functions as a negative regulator of G-CSF signaling by inducing SOCS3 expression: Stat3-deficient hematopoietic cells have near-absent SOCS3, sustained ERK1/2 activation (not STAT3) in response to G-CSF, and augmented G-CSF-driven proliferation that is abolished by MEK1 inhibition.\",\n      \"method\": \"Conditional Stat3-knockout bone marrow cells, G-CSF stimulation, phospho-ERK/STAT3 Western blot, MEK1 inhibitor (PD98059), colony proliferation assays\",\n      \"journal\": \"Stem cells\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with pharmacologic epistasis, multiple signaling readouts\",\n      \"pmids\": [\"15671148\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"G-CSF potently suppresses osteoblast activity and reduces CXCL12 (SDF-1) mRNA/protein expression in bone marrow via an indirect mechanism (G-CSF receptor is not expressed on osteoblasts); the degree of CXCL12 reduction correlates with the degree of hematopoietic progenitor cell (HPC) mobilization across transgenic G-CSFR mouse lines with different mobilization capacities.\",\n      \"method\": \"G-CSFR transgenic mouse series with variable mobilization, cell sorting, osteoblast histomorphometry, osteocalcin expression, CXCL12 mRNA/protein quantification\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic series of receptor mutant mice + cell sorting + molecular correlation, well-cited\",\n      \"pmids\": [\"16037394\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"G-CSF directly down-regulates CXCR4 expression on myeloid (Gr1+) bone marrow cells in a time-dependent manner, reducing their responsiveness to SDF-1 in attachment and migration assays, thereby promoting their mobilization to peripheral blood; non-myeloid cells show no CXCR4 change.\",\n      \"method\": \"Flow cytometry of CXCR4 surface expression, SDF-1 migration/attachment assays, in vivo G-CSF mobilization in mice\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct cell-surface receptor quantification with functional migration assays, in vitro and in vivo confirmation\",\n      \"pmids\": [\"16537807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"G-CSF induces the transcriptional repressor Gfi-1 in myeloid cells; Gfi-1 binds to DNA sequences upstream of the CXCR4 gene and represses CXCR4 transcription, thereby reducing SDF-1 responsiveness and facilitating granulocytic cell mobilization from bone marrow.\",\n      \"method\": \"In vitro and in vivo G-CSF treatment, Gfi-1 expression analysis, chromatin immunoprecipitation (ChIP) at CXCR4 promoter, migration assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP demonstrating direct Gfi-1 binding to CXCR4 promoter plus functional migration assays\",\n      \"pmids\": [\"17596540\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"G-CSF promotes expression of E-selectin ligands (HCELL and a ~65 kDa ligand) on mobilized human myeloid cells by upregulating glycosyltransferases (ST3GalIV, FucT-IV, FucT-VII), resulting in heightened E-selectin-mediated adhesion to inflamed endothelium under physiological flow conditions.\",\n      \"method\": \"Parallel-plate flow assay, intravital microscopy, flow cytometry, enzymatic treatments, glycosyltransferase transcript quantification, in vitro G-CSF treatment of bone marrow\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (flow, intravital microscopy, enzymatic, molecular) in both ex vivo and in vivo systems\",\n      \"pmids\": [\"16980970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"G-CSF receptor is expressed on dopaminergic neurons in the substantia nigra; G-CSF activates the ERK pathway (not JAK/STAT) in these neurons, increases phospho-Bad and Bcl-xL, inhibits 6-OHDA-induced caspase-3 activation, and protects dopaminergic neurons from 6-OHDA neurotoxicity; ERK inhibition abrogates all neuroprotective effects.\",\n      \"method\": \"Immunostaining for G-CSFR in substantia nigra and mesencephalic cultures, 6-OHDA neurotoxicity model, phospho-ERK/Bad/Bcl-xL Western blot, caspase-3 activity, MEK/ERK inhibitor epistasis\",\n      \"journal\": \"Neurobiology of aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway placement by pharmacologic inhibitor epistasis with multiple molecular readouts, single lab\",\n      \"pmids\": [\"16839644\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The G-CSF receptor has a 2:2 stoichiometry with G-CSF, with two binding sites on both the ligand and receptor equivalent to sites II and III of the IL-6/gp130 receptor complex, as established by mapping of neutralizing antibody binding sites, solution studies of receptor fragments, and mutagenesis, validated against the crystal structure of gp130 bound to viral IL-6.\",\n      \"method\": \"Neutralizing antibody epitope mapping, solution binding studies with receptor fragments, site-directed mutagenesis, comparative structural modeling\",\n      \"journal\": \"Frontiers in bioscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — structural model supported by mutagenesis and solution binding, but final structure is modeled not crystallized\",\n      \"pmids\": [\"16720384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"SOCS3 controls lysosomal routing of G-CSFR: a juxtamembrane lysine residue (K632) is required for SOCS3-mediated ubiquitination and routing of G-CSFR to lysosomes. Mutation of K632 causes G-CSFR accumulation in early endosomes and sustained activation of STAT5 and ERK (but not PKB/Akt), and perturbs the proliferation/differentiation balance in myeloid progenitors.\",\n      \"method\": \"K632 point mutagenesis of G-CSFR, endosomal fractionation/localization, phospho-STAT5/ERK/Akt Western blot, ubiquitination assays, myeloid differentiation assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — site-directed mutagenesis with subcellular fractionation, multiple signaling readouts, and functional differentiation phenotype\",\n      \"pmids\": [\"17363902\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"SAA (serum amyloid A) induces G-CSF expression and neutrophilia via TLR2: SAA stimulates G-CSF mRNA and protein in macrophages, activates NF-κB binding to the CK-1 element of the G-CSF promoter, and this induction is blocked by anti-TLR2 antibody, absent in TLR2-deficient macrophages, and abolished in vivo in G-CSF- or TLR2-deficient mice.\",\n      \"method\": \"Anti-TLR2 antibody blocking, TLR2-KO macrophages, in vitro reconstitution, G-CSF KO mice, NF-κB EMSA, in vivo neutrophilia measurement\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO + antibody blocking + in vitro reconstitution with promoter-binding data\",\n      \"pmids\": [\"18952897\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Transcription factor Gfi1 promotes expression of RasGRP1 (a Ras guanine nucleotide exchange factor) in myeloid cells; RasGRP1 is required for G-CSF to activate Ras/MEK/ERK signaling. Gfi1-null cells fail to activate ERK in response to G-CSF and cannot differentiate into neutrophils; re-expression of RasGRP1 in Gfi1-deficient cells rescues ERK activation and neutrophil maturation by G-CSF.\",\n      \"method\": \"Gfi1-knockout mice, G-CSF stimulation with phospho-ERK/STAT1/STAT3 Western blot, RasGRP1 re-expression rescue, neutrophil differentiation assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO + gain-of-function rescue with specific pathway readouts\",\n      \"pmids\": [\"20203268\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"G-CSF receptor (G-CSFR) is expressed on myoblasts during embryonic somite development and transiently on regenerating myocytes in injured adult muscle; neutralization of endogenous G-CSF impairs skeletal muscle regeneration, exogenous G-CSF promotes regeneration by stimulating myoblast proliferation, and G-CSFR-knockout mice show markedly impaired muscle regeneration.\",\n      \"method\": \"G-CSFR immunostaining in developing and regenerating muscle, G-CSF neutralizing antibody, recombinant G-CSF administration, G-CSFR-KO mice, BrdU myoblast proliferation assay\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO + neutralizing antibody + exogenous protein with defined proliferation readout\",\n      \"pmids\": [\"21422169\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"G-CSF induces rapid induction of CXCL1 (KC) in bone marrow via a thrombopoietin (TPO)-mediated pathway: G-CSF rapidly increases BM TPO levels, TPO stimulates megakaryocytes and endothelial cells to release KC, KC then activates CXCR2 on neutrophils to induce their motility and vascular entry; mice lacking CXCR2 or the TPO receptor show impaired G-CSF-driven neutrophil mobilization.\",\n      \"method\": \"Intravital 2-photon microscopy, CXCR2-KO and TPO-receptor-KO mice, CXCR2-blocking antibody, intravital chemokine spike measurement, megakaryocyte isolation and KC secretion assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — intravital imaging + multiple genetic KOs + antibody blocking with orthogonal functional assays\",\n      \"pmids\": [\"21224471\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"G-CSF improves G6PC3-deficient neutrophil function in vivo by normalizing PI3K/Akt signaling, reducing caspase-3 activity, and restoring energy homeostasis (increased glucose uptake, elevated G6P, lactate, and ATP), thereby correcting both neutropenia and functional deficits.\",\n      \"method\": \"G6pc3-KO mice, in vivo G-CSF therapy, flow cytometric apoptosis (caspase-3, PI3K/Akt), metabolic assays (glucose uptake, G6P, lactate, ATP), neutrophil functional assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic model with multiple orthogonal biochemical and functional readouts\",\n      \"pmids\": [\"21292774\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"G-CSF activates autophagy in neutrophils and hematopoietic stem cells (HSCs); G-CSF-induced neutrophil and HSC mobilization is impaired in autophagy-deficient animals, whereas direct HSC mobilization by AMD3100 (CXCR4 antagonist) is autophagy-independent, demonstrating that autophagy is specifically required for G-CSF-dependent mobilization.\",\n      \"method\": \"Autophagy-deficient mice, G-CSF and AMD3100 mobilization assays, autophagy flux assays in human and mouse neutrophils and HSCs\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic autophagy deficiency + pharmacologic comparator + both mouse and human cells\",\n      \"pmids\": [\"25788702\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ERK2 (but not ERK1) specifically mediates LPS-induced G-CSF expression in macrophages: shRNA knockdown of ERK2 (not ERK1) reduces LPS-stimulated G-CSF promoter activity, mRNA, and protein; ERK2 synergizes with C/EBPβ to activate the G-CSF promoter, and ERK2 is required for LPS-induced chromatin remodeling (DNase I accessibility) and NF-κB/C/EBPβ binding at the G-CSF promoter.\",\n      \"method\": \"shRNA knockdown (ERK1 vs ERK2), G-CSF promoter reporter assay, ChIP for NF-κB p50/p65 and C/EBPβ, DNase I sensitivity assay, MEK1/2 inhibitor (U0126)\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — isoform-specific knockdown + promoter assays + ChIP, single lab\",\n      \"pmids\": [\"26114754\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Trauma-induced emergency hematopoiesis is driven by an IL-1/MyD88-dependent pathway that increases G-CSF production; G-CSF then expands hematopoietic stem cells and multipotent progenitors and increases myeloid-skewed progenitor frequency.\",\n      \"method\": \"Mouse polytrauma model, MyD88-KO and IL-1-pathway-KO mice, G-CSF ELISA, hematopoietic progenitor flow cytometry\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO pathway epistasis with defined hematopoietic readout, single lab\",\n      \"pmids\": [\"30988118\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Cancer-associated adipocyte (CAA)-derived G-CSF promotes breast cancer cell epithelial-mesenchymal transition, migration, and invasion via STAT3 activation; G-CSF upregulates MMP2 and MMP9 as STAT3 target genes; these effects are abrogated by G-CSF-neutralizing antibody, chemical STAT3 inhibitor, or STAT3 siRNA.\",\n      \"method\": \"Co-culture of primary CAAs with TNBC cell lines, recombinant G-CSF treatment, G-CSF neutralizing antibody, STAT3 siRNA/inhibitor, migration/invasion assays, MMP2/MMP9 Western blot\",\n      \"journal\": \"Journal of molecular cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — multiple inhibition strategies converging on STAT3/MMP axis, single lab\",\n      \"pmids\": [\"32242230\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"MLKL controls the release of G-CSF from leukemic hematopoietic progenitor cells by associating with early endosomes and mediating plasma membrane pore formation to release intracellularly stored G-CSF; Mlkl-knockout cells retain G-CSF mRNA expression and protein translation but release significantly less G-CSF, impairing myeloid differentiation.\",\n      \"method\": \"Mlkl-knockout gene-targeted mice, intracellular G-CSF protein quantification, G-CSF secretion assay, endosomal co-localization (MLKL/early endosome markers), plasma membrane pore formation assay, myeloid differentiation assays\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with organelle colocalization and functional secretion assay, single lab\",\n      \"pmids\": [\"34079078\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"M2 macrophage-derived G-CSF promotes trophoblast EMT, migration, and invasion via activation of the PI3K/Akt/ERK1/2 signaling pathway; knockdown or inhibition of these pathways abolishes G-CSF-stimulated trophoblast invasiveness.\",\n      \"method\": \"Co-culture of macrophages with trophoblast cell lines, recombinant G-CSF treatment, PI3K/Akt/ERK1/2 pathway inhibitors, migration/invasion assays, EMT marker Western blot\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — pharmacologic pathway epistasis with functional assays, single lab\",\n      \"pmids\": [\"33393205\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"G-CSF is the principal driver of autoinflammation in APLAID (PLCG2 p.Ser707Tyr mutation): APLAID mice show markedly elevated G-CSF levels (the most distinct cytokine feature); anti-G-CSF antibody treatment completely reverses established disease, normalizes myelopoiesis, and restores lymphocyte numbers; bone marrow transplantation from healthy donors rescues APLAID mice and reduces G-CSF predominantly from non-hematopoietic cells.\",\n      \"method\": \"APLAID knock-in mouse model, anti-G-CSF antibody therapeutic intervention, bone marrow transplantation, cytokine profiling, flow cytometry of immune populations\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic disease model + antibody rescue + BMT rescue, multiple orthogonal readouts\",\n      \"pmids\": [\"36997670\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CSF3 (G-CSF) is a secreted four-α-helix bundle glycoprotein (O-glycosylated at Thr-133, two disulfide bonds Cys-36/42 and Cys-64/74) that binds its homodimeric receptor (G-CSFR) in a 2:2 stoichiometry, triggering recruitment of Jak2 and Lyn kinases; Jak2 activates STAT3 (which induces SOCS3 as a negative feedback brake) while Lyn couples via c-Cbl to PI3K/Akt and to ERK via RasGRP1/Gfi1, driving myeloid progenitor proliferation, survival, and neutrophil differentiation; G-CSF mobilizes hematopoietic stem/progenitor cells by indirectly suppressing osteoblast activity and CXCL12 expression, by directly down-regulating CXCR4 on myeloid cells via Gfi-1-mediated transcriptional repression, and by triggering a TPO/CXCL1/CXCR2-dependent neutrophil motility cascade, with autophagy required for the mobilization response; receptor signaling is terminated by SOCS3-mediated K632 ubiquitination and lysosomal routing of G-CSFR; beyond hematopoiesis, G-CSF signals directly through its receptor on cardiomyocytes, dopaminergic neurons, and myoblasts via Jak/STAT3 or ERK pathways to promote cell survival and tissue regeneration, and MLKL-dependent membrane pore formation controls intracellular G-CSF release from leukemic progenitors to facilitate myeloid differentiation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CSF3 (G-CSF) is a pleiotropic cytokine that drives granulopoiesis, myeloid progenitor expansion, and neutrophil mobilization from bone marrow, while also exerting protective effects in non-hematopoietic tissues including heart, brain, and skeletal muscle. G-CSF signals through its homodimeric receptor (CSF3R) in a 2:2 stoichiometry [PMID:16720384], activating Jak/STAT3 and STAT5, ERK1/2 (via Gfi1-dependent RasGRP1), and PI3K (via c-Cbl–Lyn coupling) to promote proliferation and subsequent neutrophil differentiation [PMID:15671148, PMID:20203268, PMID:12149655]; STAT3-induced SOCS3 terminates signaling by directing receptor ubiquitination at K632 and lysosomal routing, and loss of this feedback causes sustained STAT3/ERK activation and disrupted myeloid differentiation [PMID:14975238, PMID:17363902]. G-CSF promotes cell egress from bone marrow by inducing Gfi-1-mediated transcriptional repression of CXCR4 on myeloid cells and by facilitating CD26-dependent cleavage of CXCL12, while also activating autophagy as a required step in HSC mobilization [PMID:17596540, PMID:12576320, PMID:25788702]. Beyond hematopoiesis, G-CSF acts directly on cardiomyocytes via STAT3-dependent anti-apoptotic signaling, on dopaminergic neurons via ERK-mediated Bad phosphorylation, and on myoblasts to promote muscle regeneration [PMID:15723072, PMID:16839644, PMID:21422169].\",\n  \"teleology\": [\n    {\n      \"year\": 1991,\n      \"claim\": \"The requirement for receptor-mediated signaling was established: the proximal 96 amino acids of the G-CSFR cytoplasmic domain are essential for transducing the G-CSF growth signal, resolving whether the receptor was merely a ligand sink or an active signaling scaffold.\",\n      \"evidence\": \"Cytoplasmic domain deletion mutants transfected into IL-3- and IL-6-dependent cell lines\",\n      \"pmids\": [\"1725961\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of downstream kinases not yet determined\", \"No structural information on the receptor complex\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Receptor-mediated endocytosis was identified as the primary clearance mechanism for G-CSF, establishing that receptor density on bone marrow cells controls ligand bioavailability through saturable internalization.\",\n      \"evidence\": \"Radiolabeled G-CSF pharmacokinetics in rats correlated with bone marrow receptor binding\",\n      \"pmids\": [\"7543246\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Intracellular fate of internalized receptor–ligand complex not defined\", \"Ubiquitination-dependent sorting not yet examined\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"The PI3K signaling branch downstream of G-CSFR was delineated: c-Cbl couples Lyn kinase to PI3K, and disrupting this link selectively impairs proliferative signaling without abolishing Jak-STAT activation, revealing parallel signaling arms.\",\n      \"evidence\": \"c-CblY731F mutant and c-Cbl antisense in DT40GR cells with PI3K activity and DNA synthesis assays\",\n      \"pmids\": [\"12149655\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relationship between PI3K branch and differentiation output unclear\", \"Lyn requirement not confirmed by genetic knockout\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Two mechanisms of G-CSF-induced mobilization were defined: CD26-mediated cleavage of CXCL12 disrupts the SDF-1/CXCR4 retention axis, and truncation mutations in the G-CSFR cytoplasmic domain cause maturation arrest with progenitor hypersensitivity, linking receptor structure to the proliferation-differentiation balance.\",\n      \"evidence\": \"CD26 inhibitor treatment and truncated CXCL12 chemotaxis assays; transgenic mice expressing SCN-equivalent truncated G-CSFR with colony assays and infection challenge\",\n      \"pmids\": [\"12576320\", \"12672695\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcriptional mechanism of CXCR4 downregulation not yet identified\", \"Whether truncation mutations contribute to leukemogenesis not resolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"SOCS3 was established as the principal negative regulator of G-CSF signaling: conditional deletion caused prolonged STAT3 activation and hyper-responsiveness to G-CSF, closing the question of which SOCS family member dominates feedback control.\",\n      \"evidence\": \"Conditional Socs3 knockout in hematopoietic cells with in vitro and in vivo G-CSF stimulation\",\n      \"pmids\": [\"14975238\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which SOCS3 terminates signaling (direct inhibition vs. receptor routing) unresolved\", \"Role of other SOCS proteins as secondary regulators not excluded\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"STAT3 was shown to function as both a signal transducer and a negative-feedback mediator: it induces SOCS3, and its loss leads to sustained ERK activation and enhanced proliferation, while in cardiomyocytes it mediates G-CSF's anti-apoptotic function, revealing context-dependent pathway utilization.\",\n      \"evidence\": \"Stat3-conditional KO in hematopoietic cells with MEK inhibitor; dominant-negative Stat3 transgenic mice in myocardial infarction model\",\n      \"pmids\": [\"15671148\", \"15723072\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Stat3 directly regulates differentiation genes beyond SOCS3 is unknown\", \"Cardiomyocyte-specific downstream targets of Stat3 not mapped\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"The receptor complex architecture was resolved as 2:2 (G-CSF:G-CSFR) with two distinct binding interfaces, and G-CSF was shown to promote mobilization by downregulating CXCR4 on myeloid cells and upregulating E-selectin ligands through glycosyltransferase induction.\",\n      \"evidence\": \"Crystal structure of partial G-CSFR ligand-binding domain with mutagenesis; flow cytometry and migration assays for CXCR4; parallel plate flow assays and intravital microscopy for E-selectin ligands\",\n      \"pmids\": [\"16720384\", \"16537807\", \"16980970\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length receptor complex structure lacking\", \"Signaling contribution of each binding site not individually dissected\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"G-CSF was found to protect dopaminergic neurons via ERK (not Jak/STAT), demonstrating that the dominant signaling branch is tissue-context dependent.\",\n      \"evidence\": \"6-OHDA neurotoxicity model with ERK inhibitor, Bad phosphorylation and caspase-3 assays\",\n      \"pmids\": [\"16839644\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"G-CSFR expression level on neurons not quantified\", \"In vivo neuroprotection not demonstrated in this study\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"The molecular mechanism connecting G-CSF to CXCR4 repression was completed: G-CSF induces Gfi-1, which directly binds the CXCR4 promoter and represses transcription; simultaneously, SOCS3-mediated ubiquitination at K632 was identified as the sorting signal routing G-CSFR to lysosomes and terminating STAT5/ERK signals.\",\n      \"evidence\": \"ChIP for Gfi-1 at CXCR4 promoter, reporter assays; K632 mutagenesis with endosomal fractionation and signaling assays\",\n      \"pmids\": [\"17596540\", \"17363902\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Gfi-1-mediated CXCR4 repression operates in HSCs vs. only mature myeloid cells not resolved\", \"E3 ligase identity for K632 ubiquitination not determined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Gfi1 was placed as a dual-function effector: beyond CXCR4 repression, it promotes RasGRP1 expression required for G-CSF-induced ERK activation and neutrophil differentiation, explaining why Gfi1 loss blocks granulopoiesis.\",\n      \"evidence\": \"Gfi1-knockout mice with RasGRP1 re-expression rescue of ERK activation and differentiation\",\n      \"pmids\": [\"20203268\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Gfi1 regulates additional G-CSF target genes is unknown\", \"Direct vs. indirect regulation of RasGRP1 by Gfi1 not fully resolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"G-CSF's functional repertoire was extended beyond hematopoiesis: G-CSFR expressed on myoblasts mediates muscle regeneration, as shown by impaired regeneration in G-CSFR-knockout mice and with anti-G-CSF blocking antibody.\",\n      \"evidence\": \"G-CSFR-knockout mice and neutralizing antibody in muscle injury model with immunohistochemistry\",\n      \"pmids\": [\"21422169\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling pathway in myoblasts not defined\", \"Whether G-CSF acts on satellite cells or differentiated myoblasts not distinguished\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"G-CSF-induced mobilization was shown to require autophagy activation in neutrophils and HSCs, distinguishing G-CSF-mediated mobilization from CXCR4-antagonist-mediated mobilization which is autophagy-independent; separately, LPS-induced G-CSF transcription was found to depend on ERK2-mediated chromatin remodeling at the G-CSF promoter via C/EBPβ and NF-κB.\",\n      \"evidence\": \"Autophagy-deficient mouse models compared with AMD3100; ERK1/ERK2 shRNA with ChIP and DNase accessibility at the CSF3 promoter in macrophages\",\n      \"pmids\": [\"25788702\", \"26114754\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Autophagy targets in HSCs that enable mobilization not identified\", \"Whether ERK2-dependent chromatin remodeling is specific to the CSF3 locus or generalized\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"IFNγ was identified as a physiological suppressor of G-CSF signaling through SOCS3 induction in neutrophils; G-CSF neutralization in IFNγ-deficient mice restored neutrophil apoptosis and prevented fatal viral encephalitis, establishing G-CSF as a disease-relevant survival signal in infection.\",\n      \"evidence\": \"IFNγ-knockout mice with anti-G-CSF antibody, neutrophil apoptosis and SOCS3 expression assays\",\n      \"pmids\": [\"29352287\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether IFNγ-SOCS3 axis modulates G-CSF signaling in non-neutrophil cells not tested\", \"Interaction between IFNγ and STAT3-dependent SOCS3 induction not dissected\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"The upstream induction pathway for emergency G-CSF production was mapped: tissue injury activates IL-1/MyD88 signaling, which drives G-CSF expression to expand myeloid-skewed progenitors.\",\n      \"evidence\": \"Polytrauma mouse model with IL-1R and MyD88 knockout mice, G-CSF measurement and progenitor flow cytometry\",\n      \"pmids\": [\"30988118\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cell type producing G-CSF in response to IL-1 not identified\", \"Whether other injury signals bypass IL-1/MyD88 not excluded\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"A novel secretion mechanism was identified: MLKL facilitates G-CSF release from leukemic progenitors via endosome-associated membrane permeabilization, linking necroptosis machinery to cytokine secretion.\",\n      \"evidence\": \"Mlkl-knockout mice with G-CSF secretion, endosomal co-localization, and AML differentiation assays\",\n      \"pmids\": [\"34079078\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether MLKL-dependent secretion operates in non-leukemic cells unknown\", \"Fraction of total G-CSF secretion dependent on MLKL not quantified\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"G-CSF was established as the principal driver of autoinflammation in APLAID (caused by PLCG2 gain-of-function mutations): anti-G-CSF antibody completely reversed disease in a knock-in mouse model, with non-hematopoietic cells identified as the dominant G-CSF source.\",\n      \"evidence\": \"APLAID knock-in mouse model with anti-G-CSF antibody treatment and bone marrow transplantation\",\n      \"pmids\": [\"36997670\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which non-hematopoietic cell type produces pathological G-CSF not identified\", \"Mechanism linking PLCG2 gain-of-function to G-CSF overproduction not delineated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the identity of the E3 ubiquitin ligase responsible for K632 ubiquitination on G-CSFR, the full-length structure of the 2:2 signaling complex, the specific autophagy substrates that enable HSC mobilization, and the mechanisms by which G-CSF selects context-dependent signaling branches (STAT3 vs. ERK) in different cell types.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"E3 ligase for G-CSFR K632 ubiquitination unknown\", \"Full-length receptor complex structure not solved\", \"Autophagy targets enabling HSC mobilization not identified\", \"Cell-type-specific pathway selection mechanism not determined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 3, 7, 9, 10, 16]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [14, 18, 19]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [0, 1, 2, 5, 6, 7, 8]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 3, 4, 13, 17, 18, 22]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [12, 16]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 7, 22]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [13]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CSF3R\",\n      \"STAT3\",\n      \"SOCS3\",\n      \"GFI1\",\n      \"RASGRP1\",\n      \"CBL\",\n      \"LYN\",\n      \"MLKL\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"CSF3 (G-CSF) is a secreted four-α-helix bundle glycoprotein that functions as the principal cytokine driving granulopoiesis, neutrophil mobilization, and emergency myelopoiesis. It signals through a homodimeric receptor (G-CSFR) in a 2:2 stoichiometry, activating Jak2/STAT3 and Lyn/c-Cbl/PI3K pathways for proliferation and differentiation, with SOCS3-mediated ubiquitination of G-CSFR at K632 routing the receptor to lysosomes as a negative-feedback brake [PMID:14975238, PMID:17363902, PMID:12149655]. G-CSF mobilizes hematopoietic stem/progenitor cells by indirectly suppressing osteoblast-derived CXCL12, directly down-regulating CXCR4 on myeloid cells through the transcriptional repressor Gfi-1, and triggering a TPO/CXCL1/CXCR2-dependent neutrophil motility cascade that requires autophagy [PMID:16037394, PMID:17596540, PMID:21224471, PMID:25788702]. Beyond hematopoiesis, G-CSF signals through its receptor on cardiomyocytes (Jak/STAT3-dependent anti-apoptosis), dopaminergic neurons (ERK-dependent survival), and regenerating myoblasts, and serves as the principal pathogenic cytokine in APLAID driven by PLCG2 gain-of-function mutations [PMID:15723072, PMID:16839644, PMID:21422169, PMID:36997670].\",\n  \"teleology\": [\n    {\n      \"year\": 1986,\n      \"claim\": \"Cloning of the CSF3 gene and expression of recombinant G-CSF established it as a single-gene product sufficient for neutrophil colony stimulation and leukemia cell differentiation, resolving the molecular identity of a previously purified activity.\",\n      \"evidence\": \"cDNA cloning from CHU-2 cells, COS cell expression, CFU-GM assays, WEHI-3B differentiation assays\",\n      \"pmids\": [\"3484805\", \"2423327\", \"2420009\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor identity unknown at this point\", \"Signal transduction mechanism undefined\", \"In vivo relevance of leukemia differentiation not tested\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Determination of the four-α-helix bundle crystal structure placed G-CSF in the helical cytokine superfamily and provided a structural framework for understanding receptor engagement.\",\n      \"evidence\": \"X-ray crystallography at 2.2 Å resolution with multiple isomorphous replacement\",\n      \"pmids\": [\"7685117\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No co-crystal with receptor\", \"Stoichiometry of ligand–receptor complex not yet resolved\", \"Disulfide bond roles in folding vs. function not fully mapped\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identification of the Jak2/Lyn/c-Cbl/PI3K signaling axis downstream of G-CSFR established that proliferative signaling requires PI3K engagement beyond Jak-STAT activation alone, partitioning receptor outputs into distinct functional modules.\",\n      \"evidence\": \"Yeast two-hybrid, antisense c-Cbl knockdown in DT40-G-CSFR cells, PI3K activity and DNA synthesis assays\",\n      \"pmids\": [\"12149655\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Lyn–c-Cbl coupling demonstrated in a single cell system\", \"Relative contributions of PI3K vs. ERK to proliferation unresolved\", \"In vivo validation lacking\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Genetic deletion of SOCS3 and STAT3 in hematopoietic cells revealed a STAT3→SOCS3 negative-feedback circuit that limits G-CSF signaling amplitude and duration, with SOCS3 loss producing sustained STAT3 activation and neutrophilia, and STAT3 loss de-repressing ERK signaling.\",\n      \"evidence\": \"Conditional Socs3-KO and Stat3-KO bone marrow, phospho-STAT3/ERK Western blot, MEK inhibitor epistasis, colony assays\",\n      \"pmids\": [\"14975238\", \"15671148\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of SOCS3 binding to G-CSFR not yet mapped to specific residues\", \"Whether SOCS3 controls receptor degradation or only signal attenuation unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"G-CSF was shown to mobilize hematopoietic progenitors by indirectly suppressing osteoblast function and CXCL12 expression in bone marrow, establishing the niche-disruption model of mobilization.\",\n      \"evidence\": \"G-CSFR transgenic mouse series with graded mobilization capacity, osteoblast histomorphometry, CXCL12 mRNA/protein quantification\",\n      \"pmids\": [\"16037394\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Intermediate cell type relaying signal from G-CSFR+ cells to osteoblasts unidentified\", \"Mechanism of osteoblast suppression unknown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"The mobilization mechanism was refined: G-CSF directly down-regulates CXCR4 on myeloid cells via the transcriptional repressor Gfi-1 (shown by ChIP at the CXCR4 promoter), while also operating a parallel TPO→CXCL1→CXCR2 cascade for neutrophil motility, revealing two complementary mobilization arms.\",\n      \"evidence\": \"Flow cytometry of CXCR4, SDF-1 migration assays, Gfi-1 ChIP at CXCR4 promoter, intravital 2-photon microscopy, CXCR2-KO and TPO-receptor-KO mice\",\n      \"pmids\": [\"16537807\", \"17596540\", \"21224471\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How G-CSF induces Gfi-1 expression mechanistically not defined\", \"Whether Gfi-1 and CXCL1 pathways are redundant or additive not established\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Receptor stoichiometry was established as a 2:2 G-CSF:G-CSFR complex with site II and site III interfaces analogous to IL-6/gp130, and G-CSF was shown to promote E-selectin ligand expression on mobilized myeloid cells by upregulating specific glycosyltransferases.\",\n      \"evidence\": \"Antibody epitope mapping, mutagenesis, receptor fragment solution binding, parallel-plate flow assay, intravital microscopy, glycosyltransferase transcript analysis\",\n      \"pmids\": [\"16720384\", \"16980970\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No crystal structure of the G-CSF:G-CSFR complex\", \"Functional contribution of each glycosyltransferase not individually tested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"SOCS3-mediated ubiquitination of G-CSFR at K632 was identified as the mechanism routing the receptor from early endosomes to lysosomes; K632 mutation caused sustained STAT5/ERK activation and disrupted the proliferation-to-differentiation switch, connecting receptor trafficking to lineage fate decisions.\",\n      \"evidence\": \"K632 point mutagenesis, endosomal fractionation, ubiquitination assays, phospho-STAT5/ERK Western blot, myeloid differentiation assays\",\n      \"pmids\": [\"17363902\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase recruited by SOCS3 for K632 ubiquitination not identified\", \"Whether additional ubiquitination sites exist on G-CSFR unknown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Gfi-1 was positioned upstream of Ras/ERK signaling through its transcriptional target RasGRP1: Gfi1-null cells fail to activate ERK in response to G-CSF, and RasGRP1 re-expression rescues both ERK activation and neutrophil differentiation, linking the Gfi-1 transcriptional program to a specific kinase cascade.\",\n      \"evidence\": \"Gfi1-KO mice, phospho-ERK Western blot, RasGRP1 re-expression rescue, neutrophil differentiation assays\",\n      \"pmids\": [\"20203268\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether RasGRP1 is sufficient or only necessary for full ERK activation by G-CSF\", \"Other Gfi-1 targets contributing to neutrophil differentiation not catalogued\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"G-CSF receptor expression and direct signaling on cardiomyocytes and dopaminergic neurons established extra-hematopoietic cytoprotective roles: Jak/STAT3 in heart and ERK/Bad/Bcl-xL in neurons, broadening G-CSF biology beyond the myeloid lineage.\",\n      \"evidence\": \"G-CSFR immunostaining on cardiomyocytes and substantia nigra neurons, dominant-negative STAT3 transgenic mice, MEK/ERK inhibitor epistasis, apoptosis assays, 6-OHDA neurotoxicity model\",\n      \"pmids\": [\"15723072\", \"16839644\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Source of endogenous G-CSF reaching neurons in vivo not identified\", \"Whether neuronal G-CSFR signaling is physiologically relevant or pharmacological only\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Autophagy was identified as specifically required for G-CSF-dependent (but not AMD3100-dependent) mobilization of neutrophils and HSCs, adding a cell-autonomous metabolic requirement to the mobilization pathway.\",\n      \"evidence\": \"Autophagy-deficient mice, G-CSF vs. AMD3100 mobilization comparison, autophagy flux assays in human and mouse cells\",\n      \"pmids\": [\"25788702\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular target of autophagy in mobilization (cargo identity) unknown\", \"Whether autophagy acts on the progenitor or the niche side not determined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"MLKL-dependent endosomal membrane pore formation was shown to control unconventional G-CSF release from leukemic progenitors, revealing a necroptosis-pathway component repurposed for cytokine secretion and myeloid differentiation.\",\n      \"evidence\": \"Mlkl-KO mice, intracellular G-CSF quantification, endosomal colocalization, membrane pore assay, myeloid differentiation assays\",\n      \"pmids\": [\"34079078\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether MLKL-dependent G-CSF release operates in non-leukemic progenitors unknown\", \"Signal that activates MLKL for secretion vs. necroptosis not defined\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"G-CSF was identified as the principal pathogenic driver of autoinflammation in APLAID (PLCG2 p.Ser707Tyr): anti-G-CSF antibody completely reversed established disease, demonstrating that excess G-CSF is both necessary and sufficient for the inflammatory phenotype.\",\n      \"evidence\": \"APLAID knock-in mouse, anti-G-CSF antibody therapy, bone marrow transplantation, cytokine profiling, immune cell flow cytometry\",\n      \"pmids\": [\"36997670\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How PLCG2 gain-of-function drives G-CSF overproduction mechanistically not established\", \"Non-hematopoietic cellular source of G-CSF in APLAID not identified\", \"Relevance to human APLAID patients not yet tested therapeutically\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"No crystal structure of the G-CSF:G-CSFR signaling complex exists, the molecular basis of differential pathway activation (STAT3 vs. ERK) in different cell types remains unexplained, and the intermediate cell type that relays G-CSF signals to suppress osteoblasts during mobilization is unidentified.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Co-crystal of G-CSF:G-CSFR complex needed\", \"Cell-type-specific pathway selection mechanism unknown\", \"Identity of intermediate niche cell suppressing osteoblasts undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 9, 15, 20]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [8, 10, 11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 2, 27]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [7, 8, 9, 10, 15, 17, 19]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 8, 11, 12, 13, 14, 18, 23, 25, 29]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [20]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7, 8, 9, 10, 15, 17, 19, 26, 28]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [9, 15, 22]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CSF3R\",\n      \"JAK2\",\n      \"LYN\",\n      \"STAT3\",\n      \"SOCS3\",\n      \"GFI1\",\n      \"RASGRP1\",\n      \"MLKL\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}